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Until now, the role of cyclin dependent kinase 5 (CDK5) in cardiac pathophysiology has 
not been explored. While CDK5 has been well studied in the neuroscience/Alzheimer’s field as a 
cyclin-independent kinase, there is currently no investigation into the cardiac-specific role of 
CDK5. Recently, it was established that inhibition of CDK5 in stem cell derived cardiomyocytes 
from individuals with Timothy Syndrome (TS) rescued the delayed inactivation phenotype; TS is 
a fatal genetic long QT syndrome (LQTS) caused by delayed inactivation of the L-type voltage 
gated Ca2+channel CaV1.2. While it is evident that CDK5 plays an important role in regulating 
CaV1.2 function, its role in cardiac tissue remains to be elucidated.  
 To determine whether CDK5 is essential for cardiac function, two separate mouse models 
were established—a cardiac-deficient Cdk5 mouse model (Cdk5 flox x αMHC-MerCreMer+) and 
a Cdk5 activation mouse model via overexpression of Cdk5’s known activator, p35 (Cdk5r1/p35 
OE x αMHC-MerCreMer+). Immediately after spatiotemporal induction of deficiency/activation 
of Cdk5 in adult mice, echocardiography, histology and proteomic analysis were performed to 
examine effects on cardiac structure and function. Analysis of cardiac function and morphology 
in Cdk5 deficient mice revealed severe systolic dysfunction and a dilated cardiomyopathy-like 
phenotype. These results were further validated by a pathway analysis of quantified global 
proteome changes. Conversely, mice with an activation of Cdk5 displayed only minor changes in 
 
 
cardiac function with a modest reduction in fractional shortening and ejection fraction. Notably, 
these mice did not have any significant changes in cardiac chamber morphology, nor any 
significant changes to their global proteome. Interestingly, however, phosphoproteomic analysis 
revealed over 3,000 differentially phosphorylated proteins.  
Pathway and gene ontology analysis of proteome changes revealed significant hits related 
to cell adhesion.  Evidence for the extensively studied role of CDK5 in the brain has demonstrated 
a critical role for CDK5 kinase activity in the regulation of cell adhesion. Alterations in cell 
adhesion are observed in a number of cardiac pathologies including heart failure and dilated 
cardiomyopathy; it is therefore plausible that CDK5 potentially regulates cardiac function via cell 
adhesion mechanisms. A comparison of the phospho-proteome acutely after Cdk5 depletion vs the 
phospho-proteome acutely after Cdk5 activation, allowed for the identification of a novel cardiac-
specific Cdk5 substrate, beta taxilin (Txlnb). Validation of this potential phospho-substrate with 
an in situ proximity ligation assay demonstrated the co-localization of Cdk5-Txlnb in wildtype 
mouse cardiac tissue sections. When looking at co-localization in Cdk5 deficient tissue sections, 
no signals were observed.  
 Lastly, our lab obtained donor cardiac tissue samples from individuals who passed away 
due to either heart failure or non-cardiac causes (serving as control cardiac tissue). Analysis of 
cardiac tissue samples revealed a significant increase in both CDK5 and p35 expression in heart 
failure samples. Dysregulation of phosphorylation has been implicated in cardiac dysfunction, with 
known contribution to contractile failure and a number of cardiac pathologies including 
cardiomyopathies. These findings further support a role for CDK5 in cardiac function. 
 In conclusion, it appears that CDK5 is imperative for the maintenance of healthy cardiac 
function. Cardiac-specific homozygous and heterozygous Cdk5 deficiency revealed severe 
 
 
systolic dysfunction along with a dilated cardiomyopathy-like phenotype. While the effects of 
Cdk5 activation in the heart need to be further investigated, initial findings report significant 
downstream effects on the phosphorylation of a number of proteins, including Txlnb. Moreover, 
Txlnb was identified as a potential novel cardiac-specific substrate of Cdk5.  
The importance of identifying a role for CDK5 in the heart extends beyond this study. CDK 
inhibitors have been at the forefront of drug development for cancer therapeutics and 
immunotherapy. While modulation of CDK5 activity may be beneficial in one physiological 
system, it may prove deleterious in another. It is therefore imperative that the full range of 
molecular and physiological roles of each CDK be fully elucidated prior to therapeutic application. 
Furthermore, outcomes from this study have the potential to be translational for drug discovery 
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Chapter 1: Introduction 
 
1.1 Cyclin Dependent Kinases  
Cyclin dependent kinases (CDK’s) are a family of heterodimeric proline directed 
serine/threonine kinases that were first discovered for their indispensable role in eukaryotic cell 
cycle regulation.1,2 Traditionally, ubiquitously expressed CDK’s are activated upon binding with 
the regulatory protein subunit cyclin, having no enzymatic activity on their own.3,4 Once activated, 
CDK’s can integrate extracellular and intracellular signals for the modulation of gene transcription 
and cell cycle progression.2,5 Cyclin-CDK complexes can recognize and phosphorylate hundreds 
of protein substrates. They do so by transferring a phosphate group from adenosine triphosphate 
(ATP) to specific amino acid sequences on their protein substrate target.6,7 This mechanism yields 
two final products—a phosphorylated substrate and an adenosine diphosphate (ADP) (Fig 1). 
Because cyclin-CDK complexes can act on numerous substrates, CDK’s are central regulators in 
the coordination of simultaneous molecular events that occur during each phase of the cell cycle.3  
 
Figure 1.1: Schematic of cyclin dependent kinase phosphorylation | Cyclin dependent kinases 
selectively modify their substrates by removing a phosphate group from ATP and covalently 




CDK’s are two lobed proteins that range from about 250 to 1,500 amino acid residues in 
length.2,8 The conserved active site, a central protein kinase domain, is flanked by a small N- 
terminal and larger C-terminal lobe that contain ß-sheets and α-helices (referred to as PSAALRE), 
respectfully. The activation segment of CDK is contained within the C-terminal lobe and is 
referred to as the T-loop/activation loop. In the unbound state, CDK’s have two characteristics that 
make them inactive: (1) the T-loop is positioned in a way at the C-terminal that closes the catalytic 
cleft, preventing the binding of a protein substrate at the active-site cleft and (2) essential amino-
acid side chains in the active site are partially disordered, preventing enzymatic activity prior to 
conformational changes in the active site.8-11  
While CDK’s were traditionally thought to play a role in cell cycle regulation and gene 
expression, evolutionary divergence has resulted in an expansion in type and function of many of 
these kinases.12 CDK’s were initially discovered in yeast and frogs through both genetic and 
biochemical studies.13 There are currently 20 known CDK’s in the human genome that are 
subcategorized based on evolutionary relationship (Fig 2).13 Currently, CDK’s 1-11 have been 
most extensively studied, having mainly cell-cycle dependent roles. In summary, CDK’s 1, 2, 3, 
4, 6 and 11 play a major role in the maintenance of cell division, with known functions including 
regulation of DNA replication mitotic, progression, and regulation of growth signaling 
pathways.14,15 CDK’s 7-9 play a major role in RNA polymerase II transcription, a DNA-dependent 
RNA polymerase that functions in the transcription of genes that code for mRNA and small nuclear 
RNA’s.16 Lastly, CDK10’s main role is in cell proliferation, maintaining G2-M phase transition.2 
As previously mentioned, functional roles of certain CDK’s have evolved beyond cell cycle 
regulation, behaving as a “non-conventional” CDK. CDK5, the most unconventional and 
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diversified CDK, has known roles in cell cycle arrest and differentiation, promotion of T cell 
survival and motility, the control of β-cell insulin secretion, regulation of pain sensory pathways 
as well as neuronal migration—the known molecular and physiological roles of CDK5 will be 
addressed in the next sub section.12 
 
 
Figure 1.2: Mammalian CDK subfamilies based on evolutionary similarities| Categorization 
of CDK subfamilies is based on traditionally known functions—cell cycle (green) or gene 
transcription (yellow). Further sub-branching based on evolutionary relationships are shown via 




1.2 Structure of Cyclin Dependent Kinase 5 
One such non-conventional CDK is cyclin dependent kinase 5 (CDK5), a unique CDK in 
both activity as well as function. CDK5 is a 3.95kb stretch of DNA that has been mapped to 
chromosome 7q36.11 CDK5 is a 33 kDa proline directed serine/threonine kinase that 
phosphorylates a serine or threonine residue immediately upstream of a proline. It most commonly 
phosphorylates its substrates following the “(S/T)PX(K/H/R)” consensus motif (“S” represents 
serine, “T” represents threonine, “P” represents the requisite proline, “X” represents any amino 
acid, “K” represents glycine, “H” represents histidine and “R” represents arginine).11,17,18 CDK5 
was initially identified as a CDK in 1992 due to its high nucleotide sequence homology to CDC2 
(61%), the human homolog of Cdk1.8,12,19-21 It also shares significant homology (50-60%) with 
CDK2, CDK4 and CDK6.22 Structurally, CDK5 is quite similar to other CDK’s—it contains a 
catalytic domain (ePK) with N and C terminal lobes sharing an ATP binding site and a 20 residue 





Figure 1.3: Ribbon/Richardson diagram of CDK5-p25 complex| Ribbon/Richardson diagram of 
CDK5 (light blue) in complex with its cleaved activator, p25 (yellow). The p25 moiety is 
comprised of an NT helix, 2 C-terminal helices and a cyclin box-fold domain. The αC-helix, 
PSAALRE, the binding site of p25 to CDK5, is shown in green. The 20-residue T- loop is shown 
in purple. Phosphorylation of the T-loop is not required for CDK5 activity (This figure is reproduced 
from Tarricone, et al.)10  
 
1.2 Regulation of Cyclin Dependent Kinase 5 
Despite significant homology with other CDK’s, CDK5s primary method of activation is 
independent of the regulatory protein cyclin. Instead, its activation is dependent upon binding with 
membrane localized p35 or p39 (as well as its cleaved counterparts p25/p29) encoded by 
CDK5R1/CDK5R2.8,11,18,21,23,24 Both CDK5-p35 and CDK5-p39 complexes localize to the cell 
membrane and can sometimes localize to the cytoskeleton.25 Unlike other CDK’s, CDK5 does not 
require phosphorylation of its T-loop at the threonine160 (Thr160) residue for activation; the 
binding of CDK5 to p35/p39 alone is sufficient for full activation. Maximum activation, however, 
can be achieved when binding of p35/p39 is joined by phosphorylation of Thr160 on the T-loop.21   
CDK5R1/p35 is the primary and most effective activator of CDK5 both in vitro and in 
vivo.24 p39 is the isoform of p35, with a 72% sequence homology in CDK5-activation domain, and 
57% homology in overall amino acid sequence.25 Prior research has shown CDK5R1/p35 to be 
essential for full physiological function of CDK5, as p39 WT/p35 null mutant mice display deficits 
in full CDK5 function resulting in cortical lamination defects, inversion of neuronal layering, 
defects in neuronal migration, seizures and sporadic adult lethality.11,12,26,27 p39 knockout mice, on 
the other hand, do not display any obvious phenotypical differences.5,26,28 Both p35 and p39 
contain an N-terminal myristoylation motif that localizes it to phospholipid  cell membranes.25 
Additionally, while p35/p39 has little amino acid sequence homology to cyclins, it adopts a cyclin-
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box tertiary structure when in complex with CDK5 that is similar to the CDK-cyclin complexes’ 
cyclin box fold domain.29 p35 is reported to have highest expression in post-mitotic neurons of the 
central nervous system.8,28 It is degraded rapidly by proteosomes, with an in vivo half-life of 
approximately 20 minutes.21,30 p35 degradation is ubiquitin-dependent, although a recent study has 
reported degradation via a ubiquitin-independent pathway in physiological conditions (Fig 1.4).31  
 
Figure 1.4: Mechanism of CDK5 activation by p35/p39 | While CDK5 is inert on its own, it 
becomes activated by translocating to the membrane and interacting with the myristoylated 
regulatory subunit p35 or p39.  p35/p39 is short lived in the cell and is subsequently degraded by 
the proteosome. p35 degradation is hypothesized to occur post-phosphorylation.   
 
In certain stressful pathophysiological conditions, p35 is cleaved into p25 by calpain, a 
calcium-dependent protease.19 This truncated form of p25 contains residues 99-307 of p35, a 
stretch of amino acids that include the CDK5 activation domain.10,23 When complexed with CDK5, 
p25 is known to hyperactivate CDK5 activity and increase its stability.23 Unlike p35, p25 does not 
get degraded easily and therefore accumulates in target tissue. Such lack of degradation causes 
dysregulation of CDK5 activity resulting in both mis-localization and abnormal phosphorylation 
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of substrates—this includes hyperphosphorylation of known substrates and phosphorylation of 
non-physiological substrates.10,11,22,23,32 Currently, CDK5 has only been biochemically purified in 
complex with p25, with the structure/complex of CDK5-p35/p39 based off of the CDK5-p25 
complex (Fig 1.3).22 While p25 presence is normally low in tissue, significant tissue accumulation 
has been reported in neurodegenerative disease states such as Alzheimer’s Disease, Amyotrophic 
Lateral Sclerosis (ALS) and Parkinson’s Disease.22,32  
 
1.3 Cyclin Dependent Kinase 5 in the Brain 
CDK5 was first purified from bovine brain microtubule fractions due to its sequence 
homology with CDK2.8,12 Initially, CDK5 was solely thought to have a role in the central nervous 
system, as p35/p39 is most abundantly expressed in post-mitotic neurons and astrocytes.11 Through 
phosphorylation of a slew of neuronal proteins, CDK5 is critical for brain development during 
embryogenesis and has essential roles in all aspects of neuronal physiology, a majority of which  
have been extensively studied.12 Some of these critical neuronal functions include regulation of 
cell-to-cell adhesion, neuronal survival, neuronal migration and differentiation, membrane 
trafficking, synaptic function/plasticity, neurite outgrowth, cytoskeletal remodeling, memory 
formation and pain signaling.11,12,21,30,32,33 Cdk5-/- mutant mice experience perinatal mortality, with 
60% reportedly dying in utero. This lack of survival has been primarily attributed to deficits in 
cortical laminar structure and cerebellar foliation. Such deficits were a result of defects in neuronal 
migration, with a lack of neuronal layering in the cerebral cortex, cerebellum and hippocampus.34 
CDK5 deficiency and hyperactivity has also been linked to several neuro-pathological 
conditions including Alzheimer’s disease, ALS, Huntington’s disease and Parkinson’s disease.33 
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Since CDK5 function has been primarily elucidated in the brain, the majority of known human 
CDK5 substrates are neuronal specific (Table 1.1).  
 
Table 1.1: Previously identified substrates of CDK5 | List of reported CDK5 substrates in the 
literature (this figure is reproduced from Dhavan and Tsai21).   
 
 
1.4 Non-Neuronal Functions of Cyclin Dependent Kinase 5  
While the role of CDK5 has been extensively studied in the brain, current literature, 
demonstrates the critical roles of CDK5 in other non-neuronal biological systems and processes. 
Some of these known functions include roles in insulin secretion, metabolism, myogenesis, the 
immune system, the lymphatic system, cell motility, apoptosis, cell cycle regulation, angiogenesis, 





Table 1.2: Known physiological functions of CDK5 | List of the known functions/mechanisms 
of CDK5 in various biological and cellular processes (this figure is reproduced from Shupp, et al).26   
 
1.5 Discovery of Cyclin Dependent Kinase 5 as a New Player in Cardiac Function  
Sudden death due to cardiac arrhythmia is the most common clinical manifestation of 
cardiovascular disease, accounting for nearly 50 percent of all cardiovascular-related mortality. 35 
Several cardiac disorders are known to contribute to the development of cardiac arrhythmia, with 
the primary contributor being ischemic heart disease. Arrhythmogenic disorders with genetic 
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origin accounts for a much small subset of all cardiac arrhythmia, around 2%. One relatively 
common congenital disorder is long QT syndrome (LQTS), estimated to occur in about 1 in 2,500 
individuals. 36,37 Inherited LQTS, the most prevalent inherited cardiac channelopathy, results from 
mutations in genes encoding ion channels/regulatory molecules implicated in the regulation of 
ventricular repolarization.38 Despite the identification of 14 disease causing genes, the underlying 
mechanisms of LQTS remain to be fully elucidated. Individuals with LQTS often develop 
ventricular tachycardia, which can lead to fainting, heart failure, as well as sudden death. 39,40 One 
such fatal LQTS, long QT syndrome type 8 (LQTS8), also termed Timothy Syndrome (TS), is 
caused by a de-novo gain-of-function mutation in the gene, Calcium Voltage-Gated Channel 
Subunit Alpha 1 C (CACNA1C). CACNA1C encodes the L-type cardiac voltage gated calcium 
channel CaV1.2. This L-type channel plays an essential role in both cardiac function and 
development, contributing to excitation-contraction (EC) coupling of the heart in synchronization 
with ryanodine receptors (RyR) in the membranes of the sarcoplasmic/endoplasmic reticulum.41 
Individuals with TS experience delayed inactivation of CaV1.2, causing an abnormally prolonged 
flow of Ca2+ ions into the cardiac muscle.37  
 
1.5 Timothy Syndrome and Cyclin Dependent Kinase 5  
Human cellular models of TS have been developed by our lab in the past by reprogramming 
patient specific skin fibroblasts to human induced pluripotent stem cells (hiPSCs). These hiPSC’s 
are subsequently differentiated into cardiomyocytes (CM’s), displaying an abnormal cardiac 
phenotype associated with TS.42,43 In prior studies, our lab found that roscovitine, a CDK inhibitor 
that can bind to and increase the voltage-dependent inactivation of CaV1.2, rescued the abnormal 
action potential and cardiac CaV1.2 channel function phenotypes. 
43 When testing several different 
roscovitine analogs/classes of CDK inhibitors, our lab found that four out of five compounds 
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capable of rescuing the TS phenotype specifically inhibited CDK5; this suggested a potential role 
for CDK5 in this LQTS (Fig 1.5). Additionally, our lab found that CDK5 activator, p35, along 
with its transcription factor, early growth response-1 (EGR1), and phosphorylated MAPK1/ERK, 
were all significantly increased in the TS-hiPSC-CM model (Fig. 1.6).44
 
Figure 1.5: Summary of Roscovitine analog and CDK inhibitor tests|  
A) Schematic illustration of roscovitine analog and CDK inhibitor tests.  
(B) A summary of the CDK targets of the positive roscovitine analogs and CDK inhibitors. 
Eighteen other roscovitine analogs did not show positive effects.  
(C) Representative traces from the MATLABbased analysis of TS CM contractions before 
treatment and 2 hr after the treatment of 2 mM CR8.  
(D) The analysis of contraction irregularity of TS CMs before treatment and 2 hr after the 
treatment of each positive compound (n = 10 for the chemical compounds and n = 5 for DMSO 
control from one TS iPSC line; the irregularity value after treatment was normalized to the 
corresponding irregularity value before treatment for each sample in each group). *p < 0.05, **p < 
0.01; Student’s t test, paired. Ros, roscovitine; Myo-B, myoseverin-B; PHA, PHA-793887. The 
replicates (n) are independent biological replicates from multiple rounds of experiments. (This 






Figure 1.6: Proposed mechanism of aberrant signaling pathways in Timothy Syndrome 
cardiomyocytes | Schematic representation of the proposed signaling pathway in Timothy 
syndrome cardiomyocytes (this figure is reproduced from Song, et. al).l44  
 
Whole exome sequencing in TS patients revealed no mutations in CDK5, CDK5R1/2, 
EGR1 or CAPN genes. This led our lab to hypothesize that increased CDK5 activity could result 
from altered Ca2+ handling due to mutations in CaV1.2. Lastly, our lab found that CDK5 
reduction/inhibition using a dominant negative (DN) mutant and shRNA alleviated cardiac 
phenotypes in the TS models associated with aberrant Cdk5 hyperactivation (Fig. 1.7).44 While it 
is evident that aberrant CDK5 activity in TS has lethal consequences, it is unclear as to what the 
role of CDK5 is at baseline, in the healthy human heart. The aforementioned studies as well as this 
current study enable us to identify CDK5 as a novel player in cardiac function and cardiac 




Figure 1.7: CDK5 inhibition alleviated the phenotypes in TS-hiPSC-CM’s | (A) Representative 
voltage-clamp recordings of Ba2+ currents in the TS CM with (+CDK5 DN) and without ( CDK5 
DN) CDK5 DN expression. ‘‘1.0 (relative)’’ means that the data points were normalized to the 
corresponding peak current value to make the traces. (B) Voltage-dependent inactivation 
percentage quantification in TS CMs with (n = 19) and without (n = 7) CDK5 DN expression. (G 
& H) The analysis of Ca2+ transient duration, half decay time, amplitude, and integrated calcium 
transients (area under curve) in the paced TS CMs with and without CDK5 DN expression (n = 7 
for the group without CDK5 DN, n = 17 for the group with CDK5 DN). (This figure is reproduced 
from Song, et. al)44  
 
1.6 Cyclin Dependent Kinase 5 Inhibitors in the Clinic  
 The importance of identifying a role for CDK5 in the heart extends beyond this study. CDK 
inhibitors have been at the forefront of drug development for cancer therapeutics and 
immunotherapy.4,45 Abnormal increases in CDK activity have been shown to result in unrestricted 
cell cycle phase transition and promote incessant proliferation, giving rise to tumorigenesis and 
malignant progression.46,47 In neu-induced breast cancer, for example, CDK4 is essential for 
tumorigenesis, with inhibition of the CDK4-cyclin D1 complex shown to suppress tumor 
formation/progression.48 CDK11 expression has shown to be significantly upregulated in biopsy 
samples from primary multiple myeloma.49 Non-cell cycle CDK’s have also been the focus of 
cancer treatment targets, including CDK58, CDK9. In colon cancer, CDK8 copy number gains of 
>60% have been observed in colorectal tumors.50 A search for active clinical trials testing CDK 
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inhibitors as of June 2021 (ClinicalTrials.gov search criteria includes: recruiting, not yet recruiting, 
active not recruiting and enrolling by invitation) returns 141 results. While the cell-cycle related 
roles of CDK’s have been extensively studied, the majority of human CDK’s have unknown roles 
in cell physiology,  particularly the more “unconventional” CDK’s including CDK5, CDK5-10-
11, CDK14-18, and CDK-20.51 While modulation of CDK activity may serve beneficial in one 
physiological system, it may prove deleterious in another.  It is therefore imperative that the full 
range of molecular and physiological roles of each CDK be fully elucidated prior to therapeutic 
application. 
Recent studies implicate a role for hyperactive activity and expression of CDK5 in a variety 
of cancer types including colon, melanoma, thyroid, breast, lung, brain, colon, leukemia and 
lymphoma (Table 1.4).52 Previously, the development of cancer therapeutics was mainly focused 
on targeting tumor-associated mutations, however, the multifaceted role of CDK5 
expression/activity in cancer targets mechanisms including tumor proliferation via the DNA 
damage response, growth, migration into secondary organs, metastatic invasion, anti-tumor 
immunity and predictions of cancer severity.21,52-56 Alternatively, other groups have suggested 
CDK5’s role as a tumor suppressor via the facilitation of apoptosis and inhibition of proliferation. 
Some of the previously studied functions of CDK5 in different human cancer have been outlined 





Table 1.3: Known roles of CDK5 in various types of cancer | (Reproduced from Pozo and Bibb).52  
Current efforts to pinpoint CDK5 and their downstream targets include small molecule 
inhibitors that occupy the ATP binding/catalytic pocket in order to impede kinase activity, termed 
CDKi’s.51 Such pharmaceutical agents, however, inhibit more than one CDK since catalytic 
pockets are highly conserved across CDK family members (Table 1.4).52 One such non-specific 
inhibitor is Flavopiridol (L86-8275), which was initially developed for the treatment of multiple 
myeloid leukemia. Flavopiridol has also been studied for treatment of autoimmune rheumatoid 
arthritis as well as atherosclerosis 57-61 Drug discovery efforts have also led to the development of  
CDK5-substrate or activator specific peptides to block CDK5 binding, with one such example 
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being AT519.62-64 Such peptide blockers are still non-specific, with AT519 known to target CDK2, 
CDK4 and CDK9 in addition to CDK5.52  
 
 
Table 1.4: List of CDK5 inhibitors previously/currently in clinical trials | The above table 
represents a partial list according to a literature search of compounds/drugs known to inhibit 
CDK5 (in addition to other CDK’s) that were used for cancer treatment.  
 
 With the widespread use of CDK inhibitors, it’s essential to elucidate the unknown 
physiological role these CDK’s play in each cell type/tissue type/organ system. Prior to findings 
from the Yazawa Lab, a role for CDK5 in the cardiovascular system had not been discussed in the 
literature. If CDK5 is to be used as a target for drug discovery, a cardiac-specific role of CDK5 at 
baseline must be known. Furthermore, modulation of CDK5 activity may provide further insight 
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into heart disease pathology and help with drug discovery for conditions lacking effective 























 Published findings from the Yazawa lab utilizing hiPSC-CM’s from TS patients carrying 
a mutation in CACNA1C have demonstrated a critical role for CDK5 in the underlying cardiac 
pathophysiology of TS.43,44 The disease causing de novo gain of function mutation, G1216A in 
CACNA1C, the gene that encodes the L-type voltage gated Ca2+ channel CaV1.2, resulted in a 
G406R mutation in CaV1.2. Due to this mutation TS-hiPSC-CM’s displayed an irregularity in 
contraction/electrical activity, excess intracellular calcium influx, abnormal calcium transients and 
prolonged action potentials. TS-hiPSC-CM’s also showed a significant increase in CDK5 activity 
along with an overexpression of CDK5R1/p35, CDK5’s known activator. Based on these findings, 
a role for CDK5 in cardiac Ca2+ channel regulation via phosphorylation in the II-III loop of CaV1.2 
was proposed. In individuals with TS, the hyper-activation of CDK5 causes cardiac Ca2+ channel 
irregularity. At baseline, however, in an individual with a healthy heart, the role of CDK5 has yet 
to be established. It is therefore the overarching goal of this study to determine whether CDK5 is 
essential for adult cardiac function. To answer this question, a novel transgenic mouse line with a 
cardiac specific temporospatial depletion of Cdk5 was established.  
Cardiac-specific Cdk5 deficiency in the adult mouse heart was achieved by generation of 
a temporal Cre-mediated knockout of Cdk5 driven by the cardiomyocyte specific Myh6 promoter. 
Murine Myh6 (located on chromosome 14:54,941,921-54,966,641) codes for the protein αMHC, 
an alpha heavy chain subunit of cardiac myosin, which is expressed exclusively in juvenile and 
adult cardiomyocytes. 65-68 It functions directly in cardiomyocyte contraction, serving as a fast 
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ATPase myosin.69,70 Using Cre-LoxP technology, commercially available Cdk5 flox mice (Cdk5 
flanked by LoxP recombinase recognition sequences) were crossed with commercially available 
αMHC-MerCreMer+ transgenic mice.  
MerCreMer consists of Cre recombinase fused to two mutated ligand binding domains 
(LBD) termed “Mer” (modified estrogen receptor).71,72 Each LBD Mer no longer has the ability to 
bind to estrogen/progesterone, however, it does have the ability to bind to a synthetic estrogen 
receptor ligand such as tamoxifen (Tam).72-76 In the absence of Tam, MerCreMer is sequestered to 
the cytoplasm by heat shock protein 90 (HSP90). Once Tam is administered, MerCreMer becomes 
unbound from HSP90 and translocates from the cytoplasm to the nucleus.71,77 This translocation 
allows for recombination of tissue/cell type-specific floxed genes, in this case, cardiac specific 




Figure 2.1: Mechanism for cardiac-specific depletion of Cdk5 using the MerCreMer Cre-LoxP 
recombinase system  
 
To characterize the phenotype of these Cdk5 deficient mice, heart histology, 
echocardiography (echo) and bottom-up tandem mass tag (TMT)-based quantitative proteomic 
studies were conducted. Results from the studies discussed in this chapter indicated severe systolic 
dysfunction in both heterozygous and homozygous depletion models, alongside development of 




To determine the non-developmental, cardiac-specific role of CDK5, a cardiac-specific 
inducible Cdk5 deficient mouse model was developed (Cdk5fl/fl or Cdk5fl/fl; αMHC-MerCreMer+). 
The Cdk5 deficient mouse was established by crossing a Cdk5fl/fl mouse (B6.129S4(Cg)-
Cdk5tm1.1Lht/J, JAX #:014156) with an αMHC-MerCreMer+ transgenic mouse (Myh6-cre/Esr1*, 
JAX #5657) (Fig 2.2). A total of four groups with four distinctive phenotypes were used for this 
study: (1) Cdk5fl/fl : αMHC-MerCreMer+, (2) Cdk5fl/+ : αMHC-MerCreMer+, (3) Cdk5fl/fl or 
Cdk5fl/fl x WT and (4) WT: αMHC-MerCreMer+. Going forward, cohort/genotype short-hand will 
read: (1) Cdk5fl/fl, (2) Cdk5fl/+ (3) WT and (4) WTMCM , respectfully. The latter two cohorts, WT 
and WTMCM, are two distinct control groups—“WT” serving as a control for Cdk5, and “WTMCM” 
serving as a control for spatiotemporal Cre recombination. For breeding efficiency purposes, WT 
mice served as the control littermate cohort in this chapter.  
 
Figure 2.2: Generation of inducible cardiac-specific Cdk5 depletion mouse model |Cdk5 flox 
line was crossed with αMHC-MerCreMer (Myh6-cre/Esr1*, JAX #5657) line. Recombination was 
inducible upon administration of Tamoxifen.   
 
At 12 weeks of age, Tam was administered via intraperitoneal (I.P.) injection to induce 
cardiomyocyte-specific Cdk5 depletion (Fig. 2.2). A high concentration of Tam is known to have 
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adverse effects on normal heart function, more so significant in male mice.79 Our lab has 
previously optimized the dosing schedule of our current lot of Tam (Sigma-Aldrich, Lot 
#WXBC1801V) to accomplish the Cdk5 deficiency in both adult male and female flox mice with 
minimal cardiotoxicity. Female mice received 50 mg/kg (~3mg/mouse total) of Tam for three 




Figure 2.3: Experimental outline |Inducing cardiac-specific Cdk5  deficiency using a previously 
optimized gender specific protocol. Male mice received 37.5 mg/kg of Tam over 5 days; female 
mice received 50mg/kg Tam over 3 days. Assay’s conducted post-Cdk5 depletion include 
echocardiography, histology, ventricular sampling and proteomic analysis.   
 
Echo measurements were taken one day post final Tam injection. An echo is a non-invasive 
ultrasound of the heart that captures real-time images to observe cardiac structure and function.80 
This technique allows for the detection of any structural or hemodynamic abnormalities that may 
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be present. 81,82  In both Cdk5fl/fl and Cdk5fl/+ mice, echo measurements indicated severe systolic 
dysfunction defined by impaired ventricular contraction (i.e. the loss of inotropy), while both WT 
and WTMCM mice were within normal limits for a standard C57B/6J mouse (Fig 2.4—A, B),.83,84 
Cdk5fl/+ and Cdk5fl/fl mice displayed a significant decrease in ejection fraction (EF) (p<0.0001): 
Cdk5fl/+: 20.81 ± 7.539, Cdk5fl/fl: 17.96 ± 7.216 vs WT: 66.49 ± 2.625 and WTMCM: 61.88  ± 7.207. 
EF represents the percentage of pooled blood the left ventricle (LV) can pump out with each 
contraction. Fractional shortening (FS), the percent change in the diameter of the LV during 
systole, was also significantly decreased in Cdk5 deficient mice vs control mice (p<0.0001): 
Cdk5fl/+: 9.483 ± 3.559, Cdk5fl/fl: 8.155 ± 3.491 vs WT: 35.92 ± 1.905 and WTMCM: 32.72  ± 4.674 
(Fig 2.4—B).   
Furthermore, echo features of a DCM-like phenotype were observed. This included LV 
chamber dilation, thinning of the LV muscle walls, systolic dysfunction and decreased contractility 
(Fig 2.4—A,B).85 Measures of left ventricular end diastolic diameter (LVEDD) were as follows: 
Cdk5fl/+: 4.453 ± 0.4904, Cdk5fl/fl: 4.612 ± 0.3882 vs WT: 3.436 ± 0.7930 and WTMCM: 3.627  ± 
0.4394.  Measures of left ventricular end diastolic volume (LVEDV) were as follows: Cdk5fl/+: 
91.63 ± 22.37, Cdk5fl/fl: 98.87 ± 18.37 vs WT: 49.02 ± 8.374 and WTMCM: 55.90  ± 18.49.  WT and 
WTMCM were statistically similar in nearly all echo read-out values, with only a slight reduction 
in FS (p<0.05), however still within standard measures for a healthy C57B/6J mouse. The slight 
difference in FS was most likely due to experimental limitations of a cardiac-specific inducible 
system, with MerCreMer translocation from the cytoplasm to the nucleus thought to have a 
transient baseline level of cardiotoxicity.79  
Lastly, there was no statistically significant difference in cardiac function between Cdk5fl/+ 
and Cdk5fl/fl cohorts. Quantitative real time PCR (qRT-PCR), however, revealed a significant 
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difference (*p<0.05) in mRNA expression between Cdk5fl/+ and Cdk5fl/fl when normalized to 
Gapdh—0.6726 ± 0.09121 vs 0.3533 ± 0.1455, respectively (Fig 2.4—C). One potential 
explanation is that Cdk5 is a haploinsufficient gene, where just one functioning copy of Cdk5 is 
not adequate to preserve gene function. Haploinsufficiency is commonly observed in a number of 
genes implicated in congenital cardiac syndromes.86 Haploinsufficiency in genes encoding 
kinases, however, are less common, but still found to exist. In mice, a heterozygous loss of function 
mutation in Cdk9 resulted in cardiac, skin and epididymis morphological deficiencies.87 Additional 
haploinsufficient kinases include liver kinase B1, a serine-threonine kinase responsible for the 
phosphorylation and activation of AMP-activated protein kinase, as well as CDK12 and 
CDK13.88,89 From this point forward, Cdk5fl/+ and Cdk5fl/fl cohorts will be collectively referred to 



















Figure 2.4: Echo analysis of cardiac structure and function in Cdk5 deficient mice| 
A) Representative echo images in M-mode from a littermate control (example from female WT 
mouse) and Cdk5 deficient mouse (example from female Cdk5fl/fl mouse).  
B) Cardiac function was measured with echocardiography. Four measured values including 
ejection fraction (EF), fractional shortening (FS) , left ventricular end diastolic diameter (LVEDD) 
and left ventricular end diastolic volume (LVEDV) are shown. WT n=21 ; WTMCM n=16 ; Cdk5fl/+ 
n=10 ; Cdk5fl/fl n=12. All error bars represent standard deviation. Statistical analysis done with on 
ordinary one-way ANOVA using Tukey’s post-hoc multiple comparison using GraphPad Prism 
8/9; P-values <0.05 were considered significant; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; mean 
± S.D ).  
C) qRT-PCR of Cdk5fl/fl Cdk5 fl/+ and littermate control (WT) mice (*p<0.05 using on ordinary one-
way ANOVA with Tukey’s post-hoc multiple comparison using GraphPad Prism 8/9, control n=4; 
Cdk5fl/fl n =5 ; Cdk5fl/fl n =4; mean ± S.D.).  
 
Histopathological analysis with Mason’s trichrome (MTS) and hematoxylin and eosin (H 
& E) stains of whole heart ventricular tissue revealed a DCM-like phenotype (Fig. 2.5—A-F). It 
should be noted that no observable histological differences were seen between WT and WTMCM 
cohorts.  
Cdk5 deficient mice had notable thinning of both the left and right ventricle walls. 
Additionally, the LV was significantly dilated in Cdk5 deficient mice. Staining with MTS revealed 
some collagen fiber deposition as indicated by the green arrows (Fig 2.5—I, K, M). H&E staining 
revealed enlarged myocytes and nuclei in Cdk5 deficient mice compared with that of WT mice 
(Fig 2.5—H, J, L). Furthermore, H&E staining appeared to show a focal myocarditis-like 
phenotype with mononuclear cell infiltrate. In summary, histological findings support a LV 


















Figure 2.5: Histopathology of ventricular cardiac tissue from 12-week old Cdk5 deficient 
mice| Representative histological images from whole heart ventricular cross-sections of 
littermate control (WT), Cdk5fl/+ and Cdk5fl/fl. Staining for morphology assessment is done with 
Mason’s Trichome stain (MTS) and hematoxylin & eosin (H&E). In the MTS slides, nuclei and 
other basophilic structures are stained purple, while smooth muscle tissue stains bright red and 
collagen fibers appear in blue. In H&E stained slides, extracellular matrix and cytoplasm stain 
pink while nuclei appear in dark blue/purple.  
A-F) Image of whole heart ventricular cross section with a scaling bar drawn to 1 mm.   
G-L) Zoomed in image from left ventricle muscle with scaling bar drawn to 100 µm  
M) Magnified and color contrasted image of a representative Cdk5 deficient mouse from TMS 
stain with signs of fibrosis 
 
 Bottom-up global and phosphoproteomic studies were conducted via liquid 
chromatography coupled with mass spectrometry (LS-MS/MS). Sixteen flash frozen whole heart 
ventricular tissue samples were lysed with urea and proteins were subsequently converted into 
peptides by tryptic digestion. The resulting peptide mixture for individual samples were labeled 





labeling. Proteins then underwent fractionation, and high throughput LS-MS/MS was used to 
analyze and quantify intact proteins. Lastly, data was analyzed for statistical significance and 
biological relevance (Fig 2.6). In this chapter, I will focus on results from global proteomic LC-
MS/MS; results from phosphoproteomic LC-MS/MS will be discussed in Chapter 4.  
 
 
Figure 2.6: Experimental setup/ bottom-up proteomic workflow for Cdk5 deficient mice 
 
Differential expression analysis of the global proteome when comparing Cdk5 deficient vs 
control mice resulted in 2,027 differentially expressed proteins (FDR = 0.05, S0=0.1) (Fig 2.7—
A,B). The top three proteins with the most significant increase in fold change were nicotinamide 
riboside kinase 2 (Nmrk2), myeloperoxidase (Mpo) and chitinase-like protein 3 (Chil3), all with 
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about a 3x fold increase. NMRK2 is a muscle-specific β1 integrin binding protein that is seldom 
expressed in healthy cardiac tissue. Significant upregulation of Nmrk2 in several different mouse 
models of DCM has been reported in the literature.90-92 NMRK2 is required for the maintenance 
of cardiac structure and function, with upregulation observed during cardiac remodeling efforts 
related to DCM.91 MPO is a leukocyte-derived enzyme and is key player in the innate immune 
response via catalysis of the formation of several reactive oxygen species (ROS) and recruitment 
of leukocytes.93,94 Elevated MPO has been implicated in heart failure, cardiac arrhythmia and 
coronary artery disease. Dysregulation of MPO is also associated with cardiac tissue damage and 
an increased risk stratification for various cardiovascular diseases. 93,95-97 Lastly, CHIL3 (also 
termed YKL-40) is an inflammatory glycoprotein that’s secreted by activated leukocytes in 
inflamed tissue. As a biomarker of cell adhesion, CHIL3 is reportedly upregulated in individuals 






Figure 2.7: Comparative analysis of the global proteome  
A) Unsupervised hierarchical clustering of 2,027 differentially expressed proteins (Cdk5 deficient 
n = 10; littermate control WT n = 6).  
B) Volcano plot showing proteins with differential abundance when comparing cardiac tissue of 
Cdk5 deficient mice vs that of littermate control. Red filled circles in the right area of the volcano 
plot represent proteins more significantly abundant in the Cdk5 deficient cohort; red filled circles 
in the left area of the volcano plot represent proteins more significantly abundant in the control 
cohort.  
C) Volcano plot representing proteins with differential abundances when comparing: (1) Cdk5fl/+ 
female vs Cdk5fl/fl female (2) Cdk5fl/+ male vs Cdk5fl/fl male (3) Cdk5 deficient female vs Cdk5 deficient 





*For each protein, significance is expressed as FDR adjusted p-value as a function of difference 
between samples (log2 fold change). FDR = 0.05, s0= 0.1. Significantly upregulated/downregulated 
proteins are shown with red circles. Figures generated with MaxQuant—Perseus software.  
 
Proteins with the most significance decrease in fold change were calcium/calmodulin-
dependent 3',5'-cyclic nucleotide phosphodiesterase 1C (Pde1c), F-box only protein 40 (Fbxo40) 
and FH1/FH2 domain-containing protein 3 (Fhod3).  PDE1C is highly expressed in human 
cardiomyocytes and is known to regulate cardiac function via cyclic AMP and cyclic GMP. 
Interestingly, the literature reports an upregulation in PDE1C during heart failure, with inhibition 
of PDE1C thought to have attenuative effects on cardiomyocyte apoptosis. A role for the 
downregulation of PDE1C at baseline has yet to be elucidated.100-103 Fbxo40, a ubiquitin ligase, is 
expressed in skeletal and cardiac muscle. In the literature, in vivo knockdown of Fbxo40 has been 
associated with induction of significant myocardial hypertrophy as well as significant thickening 
in myotubules as part of uncontrolled cardiac hypertrophy.104,105 The third most significantly 
downregulated protein, Fhod3, is a diaphanous related formin known to play a role in 
cardiomyocyte actin filament polymerization. Reduction in FHOD as well as loss of function 
mutations in FHOD3 are directly correlated with development of DCM.106,107 A list of the top 30 
up and down regulated proteins in Cdk5 deficient mice can be found in Table 2.1. 
Further hierarchical sub-clustering based on gender within each of the two cohorts was 
observed (Fig 2.7—A). Additional analysis between gender in control and Cdk5 deficient cohorts, 
was conducted to look at gender-specific differentially expressed proteins. In control mice, only 
four proteins were found to be differentially expressed: decreased expression—(1) equilibrative 
nucleoside transporter 1(Slc29a1), (2) serpin family A member 1 (Serpina1e) and increased 
expression—(3) cell division cycle-associated protein 2 (Cdca2) and (4) 60S acidic ribosomal 
protein P1(Rplp1) (Fig 2.7—C).  In Cdk5 deficient mice, however, 278 proteins were found to be 
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differentially expressed—231 proteins with a decrease in quantitative abundance and 46 with an 
increase in quantitative abundance in female mice. 
There was no observed difference in differential protein expression between heterozygous 
and homozygous Cdk5 flox mice in either the male or female cohorts (Fig. 2.7—C). This lack of 
difference between heterozygous and homozygous Cdk5 flox mice was in concordance with echo 








































































Protein Name -log(p-value) 
    
-1.80 Pde1c Isoform 1 of Calcium/calmodulin-dependent  
3',5'-cyclic nucleotide phosphodiesterase 1C 
5.417846911 
-1.42 Fbxo40 F-box only protein 40 7.566723921 
-1.36 Fhod3 FH1/FH2 domain-containing protein 3 6.85036835 
-1.28 Txlnb Beta-taxilin  6.089037256 
-1.20 Lpl Lipoprotein lipase 7.409877691 
-1.12 Smpx Small muscular protein 6.218618177 
-1.04 Corin Atrial natriuretic peptide-converting enzyme 4.208936341 
-1.04 Plin5 Perilipin-5 4.157064994 
-1.03 Fam195a MAPK regulated corepressor interacting protein 2 5.92942765 
-1.00 Txlng Gamma-taxilin 6.855783036 
-0.98 Tnni3k Serine/threonine-protein kinase TNNI3K 8.162305843 
-0.94 Cdkn1b Cyclin-dependent kinase inhibitor 1B 3.487448035 
-0.94 Gja1 Gap junction alpha-1 protein 7.537539279 
-0.90 Gpsm1 G-protein-signaling modulator 1 2.800521104 
-0.90 Ivns1abp Influenza virus NS1A-binding protein homolog 4.255728159 
-0.90 Vldlr Very low-density lipoprotein receptor 6.74018785 
-0.87 Ank1 Isoform Mu7 of Ankyrin-1 4.089605693 
-0.87 Ccdc150 Coiled-coil domain-containing protein 150 2.760771103 
-0.85 Slc25a34 Solute carrier family 25 member 34 6.170633474 
-0.84 Ppp1r14c Protein phosphatase 1 regulatory subunit 14C 5.181045513 
-0.83 Camk2d Isoform 3 of Calcium/calmodulin-dependent protein 
kinase type II subunit delta 
3.786531337 
-0.83 Zfyve21 Zinc finger FYVE domain-containing protein 21 6.187891722 
-0.83 Pkia cAMP-dependent protein kinase inhibitor alpha 4.100326452 
-0.82 Dhrs7c Dehydrogenase/reductase SDR family member 7C 6.377581815 
-0.81 Katnb1 Katanin p80 WD40 repeat-containing subunit B1 1.910021404 
-0.81 Mlip Muscular LMNA-interacting protein 6.904763124 
-0.79 Gpcpd1 Glycerophosphocholine phosphodiesterase GPCPD1 4.258580865 
-0.76 Tcp11l2 T-complex protein 11-like protein 2 3.979998014 
-0.74 Adck3 Atypical kinase COQ8A, mitochondrial 4.483254276 
-0.71 Ppp1r3a Protein phosphatase 1 regulatory subunit 3A 6.106345969 
3.05 Nmrk2 Nicotinamide riboside kinase 2 6.962376248 
3.03 Mpo Myeloperoxidase 2.735351185 
2.97 Chi3l3;Chil3 Chitinase-like protein 3 4.928590881 
2.85 Lcn2 Neutrophil gelatinase-associated lipocalin 4.398244158 
2.84 S100a9 Protein S100-A9 5.407080067 
2.80 Lgals3 Galectin-3 5.905126815 
2.78 Esr1 Estrogen receptor 10.16350906 
2.76 Ngp Neutrophilic granule protein 4.278056175 
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2.61 Chi3l4 Chitinase-like protein 4 4.653325154 
2.60 Sfn 14-3-3 protein sigma 4.686944022 
2.59 Ear2 Eosinophil cationic protein 2 5.224398378 
2.55 Ctsg Cathepsin G 2.679678427 
2.53 Hspa1a Heat shock 70 kDa protein 1A 4.779394743 
2.51 Tnnt1 Troponin T, slow skeletal muscle 5.700575621 
2.51 Hmox1 Heme oxygenase 1 6.807515762 
2.49 Ctgf CCN family member 2 9.339136873 
2.34 Tnfrsf12a Tumor necrosis factor receptor superfamily member 12A 7.03984747 
2.32 Lyz2 Lysozyme C-2 5.266438035 
2.18 Cltb Clathrin light chain B 4.382265275 
2.13 Hspa1b Heat shock 70 kDa protein 1B 4.264586952 
2.08 Tnc Tenascin 3.647974575 
2.06 Mcm5 DNA replication licensing factor MCM5 2.184882083 
1.94 Gm13889 Uncharacterized protein C11orf96 homolog 5.229940129 
1.94 Krt18 Keratin, type I cytoskeletal 18 6.396581344 
1.94 Camp Cathelicidin antimicrobial peptide 3.942329356 
1.93 Ltf Lactotransferrin 3.929013667 
1.89 Arg1 Arginase-1 4.243952584 
1.88 Aldh1a2 Retinal dehydrogenase 2 1.694566956 
1.88 Kbtbd5 Kelch-like protein 40 7.512997574 
1.84 Serpine1 Plasminogen activator inhibitor 1 4.905107551 
 
Table 2.1: Graph and corresponding list of the top 30 proteins with a decrease (green) /increase 
(red) in expression log ratio in Cdk5 deficient cardiac tissue 
 
  
 Analysis of disease-based protein networks based on global proteome changes were 
mapped using Qiagen’s Ingenuity Pathway Analysis (IPA) software. The top 5 cardiovascular 
disease hits included cardiac enlargement (p-value = 3.69E-25; 170 proteins), cardiac dilation (p-
value = 2.37E-16; 90 proteins), cardiac necrosis/cell death (p-value = 1.03E-14; 72 proteins) 
cardiac fibrosis (p-value = 9.84 E-14; 63 proteins) and cardiac dysfunction (p-value = 1.51E-13; 
74 proteins). Corresponding differentially expressed proteins with each disease state can be found 
















































































Table 2.2: Top cardiovascular disease hits derived from the global proteome of Cdk5 deficient 
mice | Top 5 cardiovascular disease-based protein networks using Qiagen’s Ingenuity Pathway 
Analysis software.  
 
  
According to protein class, the majority of differentially expressed proteins belonged to the 
subcategories of metabolite interconversion enzyme and cytoskeletal proteins, whereas biological 
process analysis revealed the majority were involved in cellular and metabolic processes. Majority 
of protein hits were found to be localized to the cytoplasm and intracellular membrane-bound 
organelles. Lastly, molecular function analysis revealed top hits associated with molecular binding 
and catalytic activity (Fig 2.10). Further molecular functional annotation clustering revealed the 
top enriched cluster to be cell to cell adherens junction/cadherin binding (Fig. 2.11). Physical cell 
to cell adhesion is crucial for the maintenance of structure and function of the heart. Neighboring 
cardiomyocytes are connected by highly organized intracellular junction structures termed 
intercalated discs (IC).108 These cardiac-specific structures are comprised of two cell adhesive 
junctions—adherens junction and desmosome, which are responsible for connecting adjacent 
cardiomyocytes to one another; this allows for synchronized contraction via electromechanical 
39 
 
coupling.108-111 In several cardiac pathophysiological states, namely cardiomyopathies, there is a 
disturbance in both expression and distribution of IC’s, specifically, lateralization of cell to cell 
adhesion.112,113 In the literature, DCM has been reported to demonstrate a significant decrease in 
cadherin expression, namely N-cadherin. An N-cadherin conditional knockout mouse model was 
shown to display modest DCM with a loss of IC’s. Consistent with this reporting, the Cdk5 
deficient global proteomic dataset revealed a statistically significant decrease in N-cadherin 




Figure 2.8: Functional classifications of differentially expressed proteins using gene ontology 
enrichment analysis| Gene ontology analysis of differentially expressed proteins in Cdk5 
deficient mice were generated using PANTHER-GO slim.  
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Figure 2.9: Functional annotation clustering in Cdk5 deficient mice | The Database for 
Annotation, Visualization, and Integrated Discovery (DAVID) v6.8 was used to generate 
molecular functional annotation clustering for global proteome changes in the Cdk5 deficient 
cohort.  The 4 top enriched clusters with their corresponding molecular functions and enrichment 
scores are displayed above. Bars show the number of protein hits  
*A “medium” classification stringency was used: similarity threshold = 0.5, linkage threshold = 













Prior to previously published findings from the Yazawa lab, a role for CDK5 in the heart 
had not been elucidated. The aim of this chapter was to determine whether Cdk5 was necessary 
for normal cardiac function in the adult heart. This was done by using a in vivo mouse model with 
a spatiotemporal knockout of Cdk5 in cardiomyocytes of C57B/6J mice at 3 months of age. Several 
measures were used to assess the cardiac phenotype in these mice including echocardiography, 
histological analysis as well as proteomic studies. Echocardiography revealed severe systolic 
dysfunction, with significant decreases in FS and EF. Additionally, significant LV dilation was 
observed with findings based on increased LVEDD, LVEDF as well as histological evidence 
showing morphology changes of LV enlargement along with LV wall thinning. Staining with H&E 
also revealed mononuclear cell infiltrate and evidence of collagen deposition. Lastly, global 
proteomic LC-MS/MS studies revealed changes in protein abundance indicative of activated 
cardiac pathophysiological pathways including cardiac enlargement, cardiac dilation, cardiac 
necrosis, cardiac fibrosis and overall cardiac dysfunction  
 Further analysis of global proteome changes in Cdk5 deficient mice including  
molecular functional annotation clustering and gene ontology enrichment analysis, revealed 
significant hits related to cell-to-cell adhesion. Evidence for the extensively studied role of CDK5 
in the brain has demonstrated a critical role for CDK5 in the regulation of cell adhesion, 
specifically via N-cadherin, a Ca2+ dependent adhesion molecule.114 Such studies have shown 
CDK5’s necessity for neuronal positioning via cadherin and integrin activity regulation as well as 
integrity of the actin cytoskeleton and microtubules.115-117 Another study looking at the role of 
CDK5 in human keratinocytes implicated CDK5 in cell-to-cell and cell-to-matrix adhesion via 
regulation of cadherins and integrins.118 In the heart, the contractile ability of the cardiac muscle 
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is maintained by integrity and synchronicity of the cell-to-cell junctions.119 In heart failure as well 
as cardiomyopathies, significant alterations in cell-to-cell junctions are observed. 120,121 
Furthermore, haploinsufficiency is abundant in genes encoding proteins implicated in structural, 
regulatory as well as cell-signaling roles.122 It is therefore plausible that CDK5 plays a significant 




















2.4 Methods  
Mouse Study Approval 
 All reported murine experiments were conducted in accordance with the Columbia 
Institutional Animal Care and Use Committee (IACUC) approved animal protocol (Protocol #: 
AC-AABK3550). All Guidelines for Care and Use of Laboratory Animals established by 
Columbia University and as stated in the protocol were strictly adhered to.  
 
Establishing Cardiac-specific Cdk5 Deficient Mouse Lines 
Cdk5 flox mice (B6.129S4(Cg)-Cdk5tm1.1Lht/J) on a B6J background were obtained from 
Jackson Laboratory (JAX; catalog # 014156). These mutant mice contain LoxP sites flanking 
exons 1-5 of the 12 total exons in the Cdk5 genomic sequence. Cdk5 flox mice were subsequently 
crossed with an αMHC-MerCreMer line (B6.FVB(129)-A1cfTg(Myh6-cre/Esr1*)1Jmk/J) from Jackson Lab 
(JAX; catalog #005657). The αMHC-MerCreMer mice contain a MerCreMer transgene targeted to the 
cardiac specific promoter, Myh6. To induce cardiac-targeted recombination, Tamoxifen ≥99% 
(Millipore Sigma; catalog #: T5648-5G) was injected intraperitonially using a 25 gauge syringe at 
12 weeks of age (diluted in 10% ethanol—90% sunflower seed oil—Millipore Sigma; catalog #: 
S5007-250mL). The dosing amount/schedule was dependent on gender of the mice. Female mice 
received 50 mg/kg over 3 consecutive days. Male mice received 37.5 mg/kg over 5 consecutive days. 
Additionally, 2 control lines were utilized for analysis—(1) Cdk5 WT : αMHC-MerCreMer+ mice and 
(2) Cdk5 fl/fl or fl/+ :α -MHC-MerCreMer WT mice.  
 
Cdk5fl/fl: αMHC-MerCreMer Mouse Genotyping:  
DNA extracted from toe cuts were used for genotyping. Three sets of primers were used to 
confirm genotype of mice: (1) Cdk5 forward: 5’ CAG TTT CTA GCA CCC AAC TGA TGT A 
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3’ and Cdk5 reverse: 5’ GCT GTC CTG GAA CTC CAT CTA TAG 3’ (2) aMHC-MerCreMer 
WT forward: 5’ TCT ATT GCA CAC AGC AAT CCA 3’ and aMHC-MerCreMer WT reverse: 
5’ CCA ACT CTT GTG AGA GGA GCA 3’ (3) aMHC-MerCreMer mutant forward: 5’ TCT ATT 
GCA CAC AGC AAT CCA 3’ and aMHC-MerCreMer mutant reverse: 5’ CCA GCA TTG TGA 
GAA CAA GG 3’. TaKaRa Ex Taq® DNA Polymerase (TaKaRa Bio USA; catalog #: RR001C) 
was used for all 3 PCR reactions.  
Genotyping Use  Primer F  
(5’ 3’) 
Primer R  
(5’ 3’) 
Band Length Tm 
Cdk5  CAG TTT CTA GCA 
CCC AAC TGA TGT A 
GCT GTC CTG GAA 
CTC CAT CTA TAG 
Mutant: 460 
Het: 460 + 660 




TCT ATT GCA CAC 
AGC AAT CCA 
CCA ACT CTT GTG 





TCT ATT GCA CAC 
AGC AAT CCA 
CCA GCA TTG TGA 





Total RNA was extracted from frozen mouse whole heart ventricular samples by utilizing the 
RNeasy mini kit (Qiagen; catalog #: 74004) and RNase-Free DNase kit (Qiagen; catalog #: 
7254). cDNA was subsequently synthesized following Invitrogen’s SuperScript III First-Strand 
Synthesis System kit (ThermoFisher Scientific; catalog #: 18080051). The resulting 21 µl sample 
of cDNA was diluted with UltraPure DNase/RNase-Free Distilled Water (ThermoFisher 
Scientific; catalog #: 10977015) at a ratio of 1:4; 1 µl of each sample was used for qRT-PCR. 
qRT-PCR was ran using TB Green Advantage qPCR Premix (TaKaRa; catalog #: 639676) and 
StepOnePlus real time PCR systems (ThermoFisher Scientific; catalog #: 4376600) using a 
MicroAmp Fast Optical 96-Well Reaction Plate (ThermoFisher Scientific; catalog #: 
4346907). Quantification was done by comparative CT using mouse Gapdh as a control 
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reference gene for normalization. qRT-PCR primer sets were as follows: (1) mouse Cdk5 
forward: 5’ ACC TGG ACC CTG CTG AGA TTG TG  3’ and mouse Cdk5 reverse: 5’ CCC 
CAT TCC TGT TTA TGA GC 3’ (2). All oligo primers were synthesized by IDT.   
 
Echocardiography Procedure 
 Echo’s were performed one day post-final Tam injection in female/male cohorts. Prior to 
performing echo’s, all mice were anesthetized using isoflurane (1-5% in oxygen via inhalation) 
using a knock-down anesthesia box for initial sedation, followed using a face mask for 
maintenance of sedation. The fur on the chest was subsequently shaved using an electric razor and 
mice were placed on a warming pad to maintain a constant body temperature of 37°C 
(±5°C).  Once anesthetized/shaved, echo’s were conducted using an iE33 ultrasound system 
(Philips Medical Systems, Andover, MA, USA) with a 15-7 L-io transducer (7-15 MHz) applied 
to the chest wall. Left-ventricular end-diastolic/end-systolic diameters (LVEDD/LVESD) and end-
diastolic/end-systolic areas (LVEDA/LVESA) were measured using a two dimensional parasternal 
short-axis view at the midpapillary level. They were taken from three beats and averaged. LV end-
diastolic/end-systolic volume (LVEDV/LVESV) were calculated with Teichholz method as 
follows: LVEDV = 7.0/(2.4+LVEDD) × LVEDD3; LVESV = 7.0/(2.4+LVESD) × LVESD3. 
Images taken in Motion-mode (M-mode) were used for determining heart rate. LV fractional 
shortening (FS), LV fractional area change (FAC), LV ejection fraction (EF), and cardiac output 
(CO) were calculated as follows: LVFS = (LVEDD-LVESD)/LVEDD × 100; LVFAC = (LVEDA-
LVESA)/LVEDA × 100; LVEF = (LVEDV-LVESV)/LVEDV × 100; CO = (LVEDV-LVESV) × 
heart rate. After echocardiography procedure, mice were allowed to recover from anesthesia and 
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were subsequently placed on a warming pad in a separate container prior to returning to their cage. 
Mice were subsequently sacrificed post-echo for further cardiac-related analysis.  
 
Mouse Cardiac Tissue Sampling  
After echo, mice were sacrificed using CO2 asphyxiation followed by cervical dislocation 
according to the Columbia University IACUC protocol, #AC-AABK3550. Whole hearts were 
excised, washed in glucose-free Tyrode’s solution (1.8mM CaCl2, 1mM MgCl2, 140mM NaCl, 5.4mM 
KCl, 10mM glucose, and 10mM HEPES—pH7) and weighed. Heart weight was normalized by tibial 
length (average of left and right tibia). The atria were separated from the ventricles and chamber pairs 
were flash frozen in liquid nitrogen and stored at -80C. For RNA extraction, frozen tissue was 
homogenized and lysed using RNeasy Lysis Buffer (Qiagen; catalog #: 79216) supplemented with β-
mercaptoethanol. Frozen tissue to be used for protein extraction was homogenized and lysed using cell 
lysis buffer (Abcam; catalog #: ab152163) supplemented with Protease Inhibitor Cocktail in DMSO 
(Sigma-Aldrich; catalog #: P8340), phosphatase inhibitor complex 2 (Sigma-Aldrich; catalog #: 
P5726) and phosphatase inhibitor complex 3 (Sigma-Aldrich; catalog #: P0044). Whole heart 
ventricular samples that were used for histology were fixed in 4% paraformaldehyde for 24 hours, 
followed by suspension in a 70% ethanol + 30% dH2O solution. Fixed ventricles were subsequently 
sectioned at 5 µM thickness and paraffin embedded in coronal orientation on microscope slides (4 
sections per slide). Slides were with H & E or MTS.  
 
Global Quantitative Proteomics by Mass Spectroscopy  
After echo, mice were sacrificed using CO2 asphyxiation followed by cervical dislocation 
according to Columbia IACUC approved protocol # AC-AABK3550. Whole hearts were 
subsequently removed, washed in Tyrode’s solution and the atria were separated from the 
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ventricles. After washing, whole heart ventricular samples were flash frozen in liquid nitrogen and 
stored at -80°C until further proteomic analysis.  
For bottom-up global quantitative proteomics, TMT-based quantitative proteomics was 
used.123 In summary frozen whole ventricular mouse tissues was lysed by bead-beating in 9M urea 
and 200mM EPPS (pH 8.5), supplemented with protease and phosphatase inhibitors. Samples were 
reduced with 5mM TCEP and alkylated with 10 mM iodoacetamide (IAA) that was quenched with 
10 mM DTT. A total of 400 μg of protein was chloroform−methanol precipitated. Protein was 
reconstituted in 200 mM EPPS (pH 8.5) and digested by Lys-C overnight and trypsin for 6h, both 
at a 1:50 protease-to-peptide ratio. Digested peptides were quantified using a Nanodrop at 280nm 
and 350 µg of peptide from each sample were labeled with 800 µg TMT reagent using 16-plex 
TMT kit.124 TMT labels were checked, 0.5 µg of each sample was pooled, desalted and analyzed 
by short SPS-MS3 method, and using normalization factor, samples were bulk mixed at 1:1 across 
all channels and 5.6 mg of bulk mixed sample was used for total proteome and phospho-proteome 
analysis. Mixed TMT-labeled sample was vacuum centrifuged and de-salted with C18 Sep-Pak 
(500mg) solid-phase extraction column. 
De-salted sample was fractionated using BPRP chromatography. Peptides were subjected 
to a 50 min linear gradient from 5 to 42% acetonitrile in 10 mM ammonium bicarbonate pH 8 at a 
flow rate of 0.6 mL/min over Water X-bridge C18 column (3.5 μm particles, 4.6 mm ID and 250 
mm in length). The peptide mixture was fractionated into a total of 96 fractions, which were 
consolidated into 31 fractions.  Fractions were subsequently acidified with 1% formic acid, and 
5% of each fraction were used for total proteome analysis. The remaining 95% of each fraction 
was further consolidated into 11 fractions for phospho-proteomics analysis (discussed in Chapter 
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4). All fractions were vacuum centrifuged to near dryness and  desalted via StageTip, and 200 mg 
Sep-Pak solid-phase extraction column. 
Thirty one desalted fractions were dissolved in 10 µl of 3% acetonitrile/0.1% formic acid 
injected using SPS-MS3. The UltiMate 3000 UHPLC system (ThermoFisher Scientific; catalog #: 
IQLAAAGABHFAPBMBFB) and EASY-Spray PepMap RSLC C18 50 cm x 75 μm ID column 
(ThermoFisher Scientific; catalog #: ES900) coupled with Orbitrap Fusion (ThermoFisher 
Scientific; catalog #: IQLAAEGAAPFADBMBCX) were used to separate fractioned peptides 
with a 5-30% acetonitrile gradient in 0.1% formic acid over 45 min at a flow rate of 250 nL/min. 
After each gradient, the column was washed with 90% buffer B for 10 min and re-equilibrated 
with 98% buffer A (0.1% formic acid, 100% HPLC-grade water) for 40 min. The full MS spectra 
were acquired in the Orbitrap Fusion™ Tribrid™ Mass Spectrometer (ThermoFisher Scientific; 
catalog #: IQLAAEGAAPFADBMBCX) at a resolution of 120,000. The 10 most intense MS1 
ions were selected for MS2 analysis. The isolation width was set at 0.7 Da and isolated precursors 
were fragmented by CID at a normalized collision energy (NCE) of 35% and analyzed in the ion 
trap using “turbo” scan speed. Following acquisition of each MS2 spectrum, a synchronous 
precursor selection (SPS) MS3 scan was collected on the top 10 most intense ions in the MS2 
spectrum. SPS-MS3 precursors were fragmented by higher energy collision-induced dissociation 
(HCD) at an NCE of 65% and analyzed using the Orbitrap.  
 
Analysis of Raw Mass Spectrometric Data  
Raw mass spectrometric data were analyzed using Proteome Discoverer 2.2 to perform 
database search and TMT reporter ions quantification. TMT tags on lysine residues and peptide N 
termini (+229.163 Da) and the carbamidomethylation of cysteine residues (+57.021 Da) were set 
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as static modifications, while the oxidation of methionine residues (+15.995 Da), deamidation 
(+0.984) on asparagine and glutamine and phosphorylation (+79.966) on serine, threonine, and 
tyrosine were set as a variable modification. Data was searched against a UniProt Mouse with 
peptide-spectrum match (PSMs) and protein-level FDR at 1% FDR. The signal-to-noise (S/N) 
measurements of each protein was be normalized so that the sum of the signal for all proteins in 
each channel was equivalent to account for equal protein loading.   
 
Analysis of Global Proteomic Results  
Peptide identification and quantification were imported into Perseus MaxQuant for 
statistical analysis (FDR<0.05) to identify proteins demonstrating statistically significant changes 
in abundance.125 The following workflow was used: the generic matrix upload for the Cdk5 
deficient global proteomic dataset was imported into Perseus. Next the “categorical annotation 
rows” function was used to assign common genotype/gender combination to each sample and  
rows were filtered based on a minimum number of valid values of 16 (i.e. only protein abundances 
with a quantifiable amount in every sample were included in the analysis). Next the filtered data 
was log transformed—log2(x). An unpaired two-sample t-test was conducted using 250 
randomizations, FDR < 0.05 and s0=0.1. Data was reported using a volcano plots for two group 
comparison. For hierarchal clustering analysis, the log transformed data was normalized using a 
Z-score (without groupings).  For differential expression analysis reflecting both gender and 
genotype differences, a multi-variate ANOVA with permutation-based FDR was ran. Statistical 









Hyperactive CDK5 activity has been implicated in the underlying cardiac pathology of TS. 
Inhibition of CDK5 in TS-hiPSC-CM’s using a range of genetic approaches and chemical 
inhibitors (i.e. PHA-793887) was shown to rescue the cellular LQTS phenotype.44  The aim of the 
next set of experiments is to examine the cardiac-specific effects of increased Cdk5 activity in a 
“healthy” heart by utilizing an in vivo murine system. As show in Chapter 2, in vivo cardiac-
specific Cdk5 deficiency in the adult mouse heart causes severe systolic dysfunction along with 
an acute DCM-like phenotype. Based on these findings, it is evident Cdk5 is necessary for cardiac 
function. While a role for Cdk5 hyperactivity in TS was shown to be correlated with a 
LQTS/cardiac-arrhythmia phenotype, the impact of Cdk5 activation in healthy/steady state 
remains to be elucidated. The goal of this chapter is to examine the effect of Cdk5 activation via 
the overexpression of its activator, p35 to determine the effects on cardiac function.  
Physiological activation of Cdk5 occurs after binding to its activator p35 (coded by the 
gene Cdk5r1).126 This Cdk5-p35 complex is membrane associated and predominately localized to 
the cytoplasm due to myristoylation of p35.25 In order to achieve increased Cdk5 activation, we 
had to overexpress p35. Overexpression of Cdk5 on its own is insufficient to increase Cdk5 activity 
since Cdk5 proteins require p35 for kinase activity. The relationship between Cdk5 activation and 
p35 overexpression has been well established in the literature both in vitro and in vivo. p35 
overexpression in neuroblastoma neuro-2a cells using a tetracycline trans-activator inducible 
system was shown to effectively increases Cdk5 activity. 127 A second group showed the effects 
51 
 
of Cdk5r1 overexpression in vivo on Cdk5 activation for the promotion of primary rat β-cell 
proliferation and subsequent insulin secretion.128  
To hyperactivate Cdk5 enzymatic activity in adult mouse hearts, an inducible human 
CDK5R1/p35 OE mouse line targeted to αMHC-MerCreMer was developed. The use of human 
CDK5R1, the mouse Cdk5r1 homolog (93% cDNA sequence match), was to distinguish between 
endogenous vs synthetically overexpressed Cdk5r1/CDK5R1 transcripts. This novel mouse line is 
the first to overexpress CDK5R1/p35 temporally and conditionally in the cardiac tissue of mice. 
CDK5R1/p35 OE mice were designed with a LoxP-Stop-LoxP (LSL) cassette under the 
strong/ubiquitously expressed CAG promoter to achieve Cre-mediated conditional activation of 
CDK5R1 gene expression. CDK5R1/p35 OE mice were crossed with an αMHC-MerCreMer line 
(refer to Chapter 2) to establish the cardiac-tissue specific, temporally regulated CDK5R1/p35 OE 
mouse line. To characterize the phenotype of these cardiac-specific CDK5R1/p35 OE mice, echo 
and bottom-up TMT-based quantitative proteomic studies were conducted. Results from these 
studies demonstrated a modest decrease in systolic function, without any noticeable structural 










Conditional CDK5R1/p35 overexpression (OE), “Rosa-Cag-LSL-Cdk5r1”, chimera mice 
were established from two mouse embryonic stem cells (mESC) #C4 and C14 clones. Once F1 
mice reached 3 months of age, they were crossed with an αMHC-MerCreMer line (B6.FVB(129)-
A1cfTg(Myh6-cre/Esr1*)1Jmk/J) from Jackson Lab (JAX; catalog #005657) (Fig 3.1). Once bred mice 
reached 3 months of age, they were injected with Tam to induce recombination and subsequent 
CDK5R1/p35 OE. In order to optimize breeding efficiency, WTMCM served as the littermate control 
cohort. The Tam dosing schedule was the same as the one used for Cdk5 deficient mice as outlined 
in Fig 2.3. Confirmation of successful recombination was done via PCR and qRT-PCR (Fig 3.2).  
 
Figure 3.1: Generation of inducible cardiac-specific CDK5R1/p35 OE mouse model 
|CDK5R1/p35 OE mice were crossed with αMHC-MerCreMer (Myh6-cre/Esr1*, JAX #5657) mice. 








Figure 3.2: Confirmation of CDK5R1/p35 transgene Expression |A) PCR validation of 
recombination in cardiac tissue. B) q-RT-PCR confirmation of CDK5R1/p35 OE in cardiac tissue 
of CDK5R1/p35 OE mice post tamoxifen injection.  
 
One day post final Tam injection, an assessment of cardiac function was performed via 
echo (Fig 3.3). Echo results showed a decline in systolic function with an EF of 35.32 ± 14.64 (vs. 
WT: 66.49 ± 2.625 and WTMCM: 61.88  ± 7.207) and an FS 17.03 ± 7.696 in CDK5R1/p35 OE 
mice (vs WT: 35.92 ± 1.905 and WTMCM: 32.72  ± 4.674  While the decline in systolic function 
was not as severe as the decline associated with Cdk5 deficiency, it was still rather significant. 
Minimal increase in LVEDD and LVEDV was observed, most likely due to recombination 
translocation artifact, as there was no statistically significant difference between the WTMCM and 
CDK5R1/p35 OE cohorts (LVEDD = 3.906 ± 0.4478; LVEDV = 67.38 ± 18.46). Furthermore, 
histological assay of CDK5R1/p35 OE hearts did not reveal any changes in structure when 




that Cdk5 activation in healthy adult male and female mice had a moderate effect on systolic 







Figure 3.3: Assessment of cardiac function in CDK5R1/p35 OE mice | 
A) Representative images of echo in M-mode from a control (example from male WTMCM mouse) 
and CDK5R1/p35 OE deficient mouse (example from a female CDK5R1/p35 OE mouse). 
B) Cardiac function was measured with echocardiography. Four measured values including 
ejection fraction (EF), fractional shortening (FS) , left ventricular end diastolic diameter (LVEDD) 
and left ventricular end diastolic volume (LVEDV) are shown. WT n=21 ; WTMCM n=16 ; 
CDK5R1/p35 OE n=12. All error bars represent standard deviation. Statistical analysis done with 
on ordinary one-way ANOVA using Tukey’s post-hoc multiple comparison using GraphPad 
Prism 8/9; P-values <0.05 were considered significant; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; 





























Figure 3.4: Histopathology of ventricular cardiac tissue from 12-week-old CDK5R1/p35 OE 
mice| Representative histological images from whole heart ventricular cross-sections of 
CDK5R1/p35 OE mice and control littermate (WTMCM). Staining for morphology assessment is 
done with Mason’s Trichome stain (MTS) and hematoxylin & eosin (H&E). In the MTS slides, 
nuclei and other basophilic structures are stained purple, while smooth muscle tissue stains 
bright red and collagen fibers appear in blue. In H&E stained slides, extracellular matrix and 
cytoplasm stain pink while nuclei appear in dark blue/purple.  
A-D) Image of whole heart ventricular cross section with a scaling bar drawn to 1 mm 
E-H) Zoomed in image from left ventricle muscle with scaling bar drawn to 100 µm  
 
 Lastly, TMT-based quantitative proteomics was performed to analyze the global and 
phospho-proteomes of CDK5R1/p35 OE mice. This chapter will only review global proteomic 
results; phosphoproteomic results will be discussed in Chapter 4. Four female and two male 
littermate control mice were used, along with 3 female and 3 male CDK5R1/p35 OE mice (Fig 
3.5). Interestingly, there were no significant changes in the global proteome (Fig 3.6). The only 
global proteome change was a 1.5-fold increase in p35. What was observed, however, were 
significant changes to the phospho-proteome which will be addressed in Chapter 4.  
 






Figure 3.6: Global proteome changes in CDK5R1/p35 OE mice | Volcano plot depicting 
differential protein expression analysis between CDK5R1/p35 OE and littermate controls 
(WTMCM). p35 was found to be the only significantly changed protein with a 1.5 fold increase in 
CDK5R1/p35 OE mice quantified. 
* Unpaired student’s t test: s0=0.1, FDR=0.05, 250 randomizations, no preservation of groupings 






In Chapter 2, a cardiac-specific Cdk5 depletion mouse model was established. Conversely, 
to increase the kinase activity of Cdk5, a Cdk5 activation mouse model was discussed in this 
chapter. Cdk5 activation was achieved via overexpression of its activator, p35. As previously 
mentioned, the functional activity of Cdk5 is solely dependent on its association with p35, with 
Cdk5 OE alone shown insufficient for increasing kinase activity. 21,128-131 When assessing the 
cardiac function of CDK5R1/p35 OE mice, we saw systolic dysfunction without any cardiac 
structural abnormalities; this is contrary to what was observed in the Cdk5 deficient cohort in 
which systolic dysfunction was more severe, accompanied by LV dilation. Systolic dysfunction 
was modestly reduced based on LVEF and LVFS values, however, dysfunction was to a much 
lesser extent than that of the Cdk5 deficient cohort. Despite a modest decrease in systolic function, 
there were no morphological or significant histological changes observed in CDK5R1/p35 OE 
mouse hearts. Lastly, a review of the global proteome of Cdk5 activated mice revealed no changes 
in the differential expression of any other protein aside from p35.  
Limitations of a cardiac-specific kinase activation model in vivo is extended to a lack of 
detection of kinase activity in vivo—this is due to a lack of in vivo kinase assay availability. The 
reason for establishing this mouse model was two-fold: (1) exploration of physiological effects of 
enhanced Cdk5 activation and (2) utilize a Cdk5 activation mouse model for the discovery of 
unknown cardiac-specific substrates.  In theory, phosphorylation of Cdk5 targets should be 
increased in CDK5R1/p35 OE mice and subsequently decreased in Cdk5 deficient hearts. The 
elucidation of potential cardiac-specific substrates may provide insight into cardiac disease states 





Establishing Cardiac-specific CDK5R1/p35 OE Mouse Line 
A novel transgenic mouse line was established in which mice with a C57B/6J background 
conditionally overexpressed Cdk5 activator, CDK5R1/p35. Conditional human CDK5R1/p35 OE 
was targeted to the ubiquitous Rosa26 locus under the CAG promoter with a LoxP-STOP-LoxP 
cassette. Human CDK5R1 cDNA transcript was used to distinguish between endogenous and 
exogenous Cdk5r1/CDK5R1. “Rosa26-Cag-LSL-Cdk5r1” chimera mice were established from 
two mouse embryonic stem cells (mESC) #C4 and C14 clones. Once F1 mice reached adult age 
(3 months), they were crossed with an αMHC-MerCreMer Cre driver line (B6.FVB(129)-
A1cfTg(Myh6-cre/Esr1*)1Jmk/J) from Jackson Lab (JAX; catalog #005657).  
 
CDK5R1/p35 OE : αMHC-MerCreMer Mouse Genotyping:  
DNA extracted from toe cuts were used for genotyping. Three sets of primers were used to 
confirm genotype of mice: (1) Rosa26 forward: 5’ GGA CTA GGG CTG CGT GAG TCT CTG 
A 3’ and Rosa26 reverse: 5’ GGC GTT ACT ATG GGA ACA TAC GTC 3’ (2) aMHC-
MerCreMer WT forward: 5’ TCT ATT GCA CAC AGC AAT CCA 3’ and aMHC-MerCreMer 
WT reverse: 5’ CCA ACT CTT GTG AGA GGA GCA 3’ (3) aMHC-MerCreMer mutant forward: 
5’ TCT ATT GCA CAC AGC AAT CCA 3’ and aMHC-MerCreMer mutant reverse: 5’ CCA 
GCA TTG TGA GAA CAA GG 3’. To confirm targeted recombination and overexpression of 
Cdk5r1/p35, the following primer set was used: (4) CDK5R1/p35 recombination F: 5’ CCG CGG 
GCC CTA AGA AGT TCC TAT TC 3’ and p35 recombination R: 5’ GTT GCG TCA GCA AAC 
ACA GT 3’. Vent DNA Polymerase (New England BioLabs; catalog #: M0254L) was used for 
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Rosa26 PCR. TaKaRa Ex Taq® DNA Polymerase (TaKaRa Bio USA; catalog #: RR001C) was 
used for the latter 3 reactions—(2), (3) and (4).  
Genotyping Use  Primer F  
(5’ 3’) 
Primer R  
(5’ 3’) 
Band Length Tm 
aMHC-
MerCreMer WT 
TCT ATT GCA CAC 
AGC AAT CCA 
CCA ACT CTT GTG 





TCT ATT GCA CAC 
AGC AAT CCA 
CCA GCA TTG TGA 
GAA CAA GG 
300 50 
 
Rosa26 GGA CTA GGG CTG 
CGT GAG TCT CTG A 
GGC GTT ACT ATG 




CCG CGG GCC CTA 
AGA AGT TCC TAT TC 
GTT GCG TCA GCA 







Total RNA was extracted from frozen mouse whole heart ventricular samples from 
CDK5R1/p35 OE or WTMCM cohorts by utilizing the RNeasy mini kit (Qiagen; catalog #: 74004) 
and RNase-Free DNase kit (Qiagen; catalog #: 7254). cDNA was subsequently synthesized 
following Invitrogen’s SuperScript III First-Strand Synthesis System kit (ThermoFisher Scientific; 
catalog #: 18080051). The resulting sample of cDNA was diluted with UltraPure DNase/RNase-
Free Distilled Water (ThermoFisher Scientific; catalog #: 10977015) at a ratio of 1:5. qRT-PCR 
was ran using TB Green Advantage qPCR Premix (TaKaRa; catalog #: 639676) and StepOnePlus 
real time PCR systems (ThermoFisher Scientific; catalog #: 4376600) using a MicroAmp Fast 
Optical 96-Well Reaction Plate (ThermoFisher Scientific; catalog #: 4346907). Quantification was 
done by comparative CT, using mouse Gapdh as a control reference gene for normalization. qRT-
PCR primer sets were as follows: (1) human CDK5R1 forward: 5’ ATG CAT TGA ATC CTT 
CAC CC 3’ and human CDK5R1 reverse: CTT CTC CGA CCT GAA GAA GC’ (2) mouse Gapdh 
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forward: 5’ AGG TCG GTG TGA ACG GAT TTG  3’ and mouse Gapdh reverse: 5’ GGG GTC 
GTT GAT GGC AAC A 3’. All oligo primers were synthesized by IDT.   
 
Global Quantitative Proteomics by Mass Spectroscopy  
After echo, mice were sacrificed using CO2 asphyxiation followed by cervical dislocation 
according to Columbia IACUC approved protocol # AC-AABK3550. Whole hearts were 
subsequently removed, washed in Tyrode’s solution and the atria were separated from the 
ventricles. After washing, whole heart ventricular samples were flash frozen in liquid nitrogen and 
stored at -80 C until further proteomic experiments.  
For bottom-up global quantitative proteomics, tandem mass tag (TMT)-based quantitative 
proteomics was used.123 In summary, flash frozen mouse ventricular heart tissue was lysed by 
bead-beating in 9M urea and 200mM EPPS (pH 8.5), supplemented with protease and phosphatase 
inhibitors. Samples were reduced with 5mM TCEP and alkylated with 10 mM iodoacetamide 
(IAA) that was quenched with 10 mM DTT. A total of 400 μg of protein was chloroform−methanol 
precipitated. Protein was reconstituted in 200 mM EPPS (pH 8.5) and digested by Lys-C overnight 
and trypsin for 6h, both at a 1:50 protease-to-peptide ratio. Digested peptides were quantified using 
a Nanodrop at 280nm and 300 µg of peptide from each sample were labeled with 800 µg TMT 
reagent using 10-plex TMT kit.124 TMT labels were checked, 0.5 µg of each sample was pooled, 
desalted and analyzed by short SPS-MS3 method, and using normalization factor, samples were 
bulk mixed at 1:1 across all channels and 100 µg of bulk mixed samples were used for total 
proteome and remaining for phospho-proteome analysis (phosphoproteomic analysis discussed in 
Chapter 4).  
Mixed TMT-labeled samples were fractionated using the High pH Reversed-Phase Peptide 
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Fractionation Kit (ThermoFisher Scientific; catalog #: 84868) and each fraction was dried down 
in a speed-vac. Peptides were dissolved in 10 µl of 3% acetonitrile/0.1% formic acid injected using 
SPS-MS3. The UltiMate 3000 UHPLC system (ThermoFisher Scientific; catalog #: 
IQLAAAGABHFAPBMBFB) and EASY-Spray PepMap RSLC C18 50 cm x 75 μm ID column 
(ThermoFisher Scientific; catalog #: ES900) coupled with Orbitrap Fusion Tribrid Mass 
Spectrometer (ThermoFisher Scientific; catalog #: IQLAAEGAAPFADBMBCX) were used to 
separate fractioned peptides with a 5-30% acetonitrile gradient in 0.1% formic acid over 127min 
at a flow rate of 250 nL/min. After each gradient, the column was washed with 90% buffer B for 
5 min and re-equilibrated with 98% buffer A (0.1% formic acid, 100% HPLC-grade water) for 
40min. For High pH Reversed-Phase proteome fractions, the full MS spectra were acquired in the 
Orbitrap Fusion Tribrid Mass Spectrometer (ThermoFisher Scientific; catalog #: 
IQLAAEGAAPFADBMBCX) at a resolution of 120,000.  
The 10 most intense MS1 ions were selected for MS2 analysis. The isolation width was set 
at 0.7 Da and isolated precursors were fragmented by CID at a normalized collision energy (NCE) 
of 35% and analyzed in the ion trap using “turbo” scan speed. Following acquisition of each MS2 
spectrum, a synchronous precursor selection (SPS) MS3 scan was collected on the top 10 most 
intense ions in the MS2 spectrum. SPS-MS3 precursors were fragmented by higher energy 
collision-induced dissociation (HCD) at an NCE of 65% and analyzed using the Orbitrap.  
 
Analysis of Global Raw Mass Spectrometric Data  
Raw mass spectrometric data was analyzed using Proteome Discoverer 2.2 to perform 
database search and TMT reporter ions quantification. TMT tags on lysine residues and peptide N 
termini (+229.163 Da) and the carbamidomethylation of cysteine residues (+57.021 Da) was set 
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as static modifications, while the oxidation of methionine residues (+15.995 Da), deamidation 
(+0.984) on asparagine and glutamine and phosphorylation (+79.966) on serine, threonine, and 
tyrosine were set as a variable modification. Data was searched against a UniProt Mouse with 
peptide-spectrum match (PSMs) and protein-level FDR at 1% FDR. The signal-to-noise (S/N) 
measurements of each protein will be normalized so that the sum of the signal for all proteins in 
each channel was equivalent to account for equal protein loading.   
 
Analysis of Global Proteomic Results  
Peptide identification and quantification were imported into Perseus MaxQuant for 
statistical analysis (FDR<0.05) to identify proteins demonstrating statistically significant changes 
in abundance.125 The following workflow was used: the generic matrix upload for CDK5R1/p35 
OE global proteomic dataset was filtered based on a minimum number of valid values of 12 (i.e. 
only protein abundances with a quantifiable amount in every sample were included in the analysis). 
Next the “categorical annotation rows” function was used to assign common genotypes to each 
sample (either “CDK5R1/p35 OE” or “WT”) and the data was subsequently log transformed—
log2(x). For differential expression analysis, a two-sample student’s T-test was ran using 
CDK5R1/p35 OE as “group 1” and “WT” as group 2. The following criteria was used for the T-








Protein phosphorylation is the most common and critical molecular regulator of protein 
function, localization, cell signaling and gene expression. Nearly 30% of all eukaryotic proteins 
are thought to be phosphorylated on at least one amino acid residue.132 The phosphorylation state 
of proteins affect their activity, reactivity and ability to bind to other molecules.133 Protein kinases 
selectively and reversibly modify other proteins by adding a hypervalent phosphate group (PO4
3-) 
from ATP to a polar alkyl group of an amino acid residue. This phosphate addition transforms a 
once hydrophobic/apolar protein to a hydrophilic/polar protein. The protein is now able to adopt a 
variety of structural changes and alterations of protein confirmation necessary for a variety of 
biological changes including interaction with other molecules, substrate specificity and subcellular 
localization. Furthermore, adoption of structural changes can also affect regulation of protein 
function including assembly or detachment of protein complexes, as well as subcellular 
localization.132-136 
Protein phosphorylation is an essential regulator of myocardial contraction and function. 
A balance between the phosphorylation/dephosphorylation state of proteins allows for 
maintenance of cardiac homeostasis.137 Cardiac Ca2+ homeostasis, in particular, is controlled by 
kinase mediated protein phosphorylation via excitation contraction coupling mechanisms. For 
example, phosphorylation of regulatory proteins by protein kinase A (PKA) activates L-type 
voltage gated Ca2+ channels to increase Ca2+ influx and facilitates the subsequent release of Ca2+ 
stored in the sarcoplasmic reticulum. Furthermore, protein phosphorylation coordinates 
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mechanisms involved in the temporal regulation of contractility, relaxation, and subsequent 
myofilament Ca2+ affinity, all to sustain Ca2+ homeostasis.119,138-140 
 A known role for phosphorylation by CDK’s in the heart has been limited to cardiac 
development and cardiomyocyte differentiation via cell cycle regulation. Cell-cycle relevant CDK 
expression is reportedly low after birth since cardiomyocytes are terminally differentiated and exit 
the cell cycle post-embryonic development.141 For example, one group showed high cardiac-
expression of CDK1, CDK2 and CDK4 throughout embryonic development and neonatal 
development, however, high levels of CDK expression subsided by the time rats reached 
adolescence. 142 Traditional cyclin-dependent CDK’s have also been implicated in states of cardiac 
stress, including cardiac hypertrophy and heart failure. Postmitotic cardiomyocytes are known to 
proliferate during end stage heart failure, with one study reporting evidence of CDK6 expression 
during heart failure in humans.141 While the aforementioned studies address the role of cell cycle 
relevant kinases, there is a lack of insight into cell cycle independent roles of CDK’s such as 
CDK5. For this reason, non- cell-cycle substrates of cyclin-independent kinases, such as CDK5, 
remain to be explored. 
 Currently, the list of known cell-cycle independent, physiologically relevant substrates of 
CDK5 are limited to the brain (Table 1.1). It is therefore the aim of this chapter to determine 
primary substrates of CDK5 in adult cardiac tissue. In this chapter, I discuss results from LC-
MS/MS phosphoproteomic analysis to identify potential cardiac-specific Cdk5 substrates. Both 
Cdk5 deficient and CDK5R1/p35 OE cohorts (day 1 post final Tam injection) were subject to 
phosphoproteomic analysis. An acute time point was used for phosphoproteomic analysis in order 
to identify immediate/primary phosphorylation changes, rather than secondary changes that may 
occur resulting from downstream impact on physiological state. A comparison of proteins with a 
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significant decrease in phosphorylation immediately after Cdk5 depletion was induced vs proteins 
with a significant increase in phosphorylation immediately after Cdk5 activation was induced, 
allowed me to narrow down potential phospho-substrates. The identified proteins were further 
validated using a proximity ligation assay, looking at the co-localization of Cdk5 + target 




















 Bottom-up phosphoproteomic analysis of the Cdk5 deficient cohort and CDK5R1/p35 OE 
cohort immediately following recombination (1 day post final Tam injection) was performed. The 
acute nature of the study serves a purpose of identifying the immediate phosphorylation changes 
due to Cdk5 deficiency/ Cdk5 activation.  
 Differential expression analysis of the phospho-proteome when comparing Cdk5 deficient 
vs control mice resulted in 538 differentially phosphorylated proteins (FDR = 0.05, S0=0.1) (Fig 
4.1). The top 30 proteins with an overall increase and top 30 proteins with an overall decrease in 
phosphorylation are included in Fig 4.1. The top three proteins with an overall significant decrease 
in phosphorylation were beta-taxilin (Txlnb), Gap junction a1 (Gja1) and formin homology 2 
domain containing 3 (Fhod3). Txlnb is a cardiac-enriched protein, with little known function.143 
Recently, decreased expression in TXLNB has been implicated in DCM.144 Further discussion of 
Txlnb will be done later on in this chapter. GJA1 is a gap junction protein/connexin with a 
prominent role in cardiac cell-to-cell adhesion, migration and signaling. 145,146 In the heart, gap 
junctions function to ensure successful propagation of the cardiac impulse by providing pathways 
for intercellular current flow and communication 147,148. Evidence of gap junction remodeling in 
which density as well as distribution of gap junctions are modified, have been implicated in nearly 
all cardiac arrhythmias. 149 In particular, dysregulation of GJA1 phosphorylation leads to gap 
junction remodeling and has been implicated in cardiac arrhythmias with GJA1 dephosphorylation 
occurring post-myocardial ischemia. The dephosphorylation event is thought to be a correlative 
mechanism with contractile failure and subsequent arrhythmia.150 Furthermore, reports of patient 
specific familial mutations in GJA1 have resulted in DCM and subsequent heart failure 151,152 
Lastly, FHOD3 is an established sarcomeric protein essential for sarcomeric organization; 
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increases in phosphorylation have been associated with cardiac hypertrophy, while 
pathophysiological effects on a decrease in phosphorylation have yet to be elucidated.153  
  The top three proteins with an overall significant increase in phosphorylation were 
chromosome 4 open reading frame 54 (C4orf54), plectin (Plec) and tenascin C (Tnc). Despite 
being highly expressed in cardiac tissue, little is known regarding the cardiac-specific function of 
C4orf54. PLEC is an intermediate filament binding protein, responsible for connecting 
cytoskeleton filaments to intracellular junction in the heart.154 Phosphorylation of PLEC has been 
shown to be directly correlated with intermediate filament interaction.155 Lastly TNC, an 
intracellular matrix protein, is known to play a crucial role in the regulation of cell adhesion as 
well as tissue remodeling in a number of cardiac disease states—a literature search did not reveal 
roles for changes in phosphorylation.156  
 
 
Figure 4.1: Comparative analysis of the Cdk5 deficient cardiac phospho-proteome  
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A) Unsupervised hierarchical clustering of differentially phosphorylated proteins between Cdk5 
deficient vs littermate control mice (Cdk5 deficient n = 10; control WT n = 6).  
B) Volcano plot representing proteins with significant differences in phosphorylated proteins 
when comparing Cdk5 deficient with control samples.  
*For each protein, significance is expressed as FDR adjusted p-value as a function of difference 
between samples (log2 fold change). FDR = 0.05, s0= 0.1. Significantly upregulated/downregulated 





Gene Symbol Gene Name -Log(p-value) 
-1.972 Txlnb taxilin beta 4.49 
-1.577 Gja1 gap junction protein alpha 1 7.54 
-1.57 Fhod3 formin homology 2 domain containing 3 7.89 
-1.425 Klhl31 kelch like family member 31 3.01 
-1.402 Palld palladin, cytoskeletal associated protein 8.56 
-1.392 Fgf13 fibroblast growth factor 13 3.58 
-1.384 Tacc2 transforming acidic coiled-coil containing protein 2 6.75 
-1.299 Chchd2 coiled-coil-helix-coiled-coil-helix domain 
containing 2 
6.09 
-1.264 Celf2 CUGBP Elav-like family member 2 5.29 
-1.241 Palmd palmdelphin 2.56 
-1.24 Ppp1r14c protein phosphatase 1 regulatory inhibitor subunit 
14C 
3.37 
-1.233 Mmachc metabolism of cobalamin associated C 5.25 
-1.166 Pde1c phosphodiesterase 1C 6.28 
-1.13 Nfib nuclear factor I B 2.71 
-1.092 Tbc1d4 TBC1 domain family member 4 3.94 
-1.076 Efnb3 ephrin B3 3.88 
-1.046 Denr density regulated re-initiation and release factor 2.23 
-1.016 Bckdha branched chain keto acid dehydrogenase E1 
subunit alpha 
2.96 
-1.015 Ppp1r3a protein phosphatase 1 regulatory subunit 3A 4.96 
-1.008 Sorbs1 sorbin and SH3 domain containing 1 5.9 
-0.998 Myoz2 myozenin 2 3.15 
-0.945 Tln2 talin 2 2.15 
-0.909 Rnf207 ring finger protein 207 4.98 
-0.884 Fyco1 FYVE and coiled-coil domain autophagy adaptor 
1 
3.13 
-0.874 Ank3 ankyrin 3 4.71 
-0.827 Pde4a phosphodiesterase 4A 5.1 
-0.81 Ndufs7 NADH:ubiquinone oxidoreductase core subunit 
S7 
3.29 
-0.806 Pde4dip phosphodiesterase 4D interacting protein 4.22 
-0.798 Sgca sarcoglycan alpha 2.78 
-0.797 Cnksr3 CNKSR family member 3 3.23 
3.728 C4orf54 chromosome 4 open reading frame 54 8.36 
3.597 Plec plectin 7.35 
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3.459 Tnc tenascin C 5.19 
3.433 Krt80 keratin 80 7 
3.351 Spp1 secreted phosphoprotein 1 4.78 
3.226 Xirp2 xin actin binding repeat containing 2 7.36 
3.124 Flnc filamin C 7.16 
3.039 Xirp1 xin actin binding repeat containing 1 7.32 
2.906 Mybpc2 myosin binding protein C2 5.21 
2.821 Ndufs3 NADH:ubiquinone oxidoreductase core subunit 
S3 
6.15 
2.628 Tpm2 tropomyosin 2, beta 6.43 
2.624 Ttn titin 4.13 
2.612 Dsp desmoplakin 9.21 
2.526 Adprhl1 ADP-ribosylhydrolase like 1 5.54 
2.518 Sptb spectrin beta, erythrocytic 8.54 
2.403 Cryab crystallin alpha B 5.93 
2.373 Jpt1 Jupiter microtubule associated homolog 1 9.21 
2.335 Rtn4 reticulon 4 8.84 
2.266 Dab2 DAB adaptor protein 2 4.89 
2.258 Trim54 tripartite motif containing 54 4.95 
2.253 Klhl9 kelch like family member 9 7.44 
2.249 Psma5 proteasome 20S subunit alpha 5 7.49 
2.246 Synpo2l synaptopodin 2 like 7.97 
2.231 Sec62 SEC62 homolog, preprotein translocation factor 5.63 
2.164 Hax1 HCLS1 associated protein X-1 5.56 
2.15 Sync syncoilin, intermediate filament protein 7.06 
2.145 Sqstm1 sequestosome 1 6.7 
2.138 Hspbp1 HSPA (Hsp70) binding protein 1 6.78 
2.137 Apobr apolipoprotein B receptor 5.87 
2.064 Obscn obscurin, cytoskeletal calmodulin and titin-
interacting RhoGEF 
6 
2.034 Tnni3 troponin I3, cardiac type 4.35 
 
Table 4.1: Graph and corresponding list of the top 30 proteins with a decrease/increase in 
phosphorylation based on fold change (log2 ratio) in Cdk5 deficient mouse cardiac tissue 
 
Differential expression analysis of the phospho-proteome when comparing CDK5R1/p35 
OE mice vs control mice resulted revealed clustering based on genotype in the twelve samples. A 
total of 3,074 differentially phosphorylated proteins/protein isoforms were found (FDR = 0.05, 
S0=0.1). The top 30 proteins with an overall increase and top 30 proteins with an overall decrease 
in phosphorylation are included in Table 4.2. The top three proteins with an overall significant 
decrease in phosphorylation were aspartate beta-hydroxylase (Asph), sorbin and SH3 domain 
containing 1 (Sorbs1) and HIV-1 Tat specific factor 1 (Htatsf1). Asph is a non-heme iron 
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containing protein that is located at the junctional sarcoplasmic reticulum in cardiac muscle; it has 
been implicated in cardiac remodeling and fibrosis.157 Sorbs1 is an adaptor protein highly 
expressed in cardiac tissue, known to regulate cell-cell adhesion and cytoskeletal formation. It is 
also highly expressed in end stage heart failure patients.158 Lastly, Htasf1 is a transcription factor 
that regulates transcriptional elongation. One published finding suggests Htasf1 functions as a 
NaV1.2 associated protein—NaV1.2 is a voltage-gated sodium channel expressed in aortic smooth 
muscle cells and cardiomyocytes, and plays a significant role in the generation propagation of 
cardiac action potentials.159,160 
Conversely, the top three proteins with an overall significant increase in phosphorylation 
were cyclase associated actin cytoskeleton regulatory protein 2 (Cap2), talin 2 (Tln2) and caveolae 
associated protein 4 (Cavin4). All three proteins are crucial for maintaining cardiac cytoskeleton 
integrity. Cap2 is a cytoskeletal protein whose exact cardiac function is unknown. The protein is 
thought to regulate cell motility and muscle contraction—Cap2 loss-of-function and conditional 
knockout mouse models displayed a DCM/sudden heart failure, respectfully.161,162 Tln2 is highly 
expressed in cardiac tissue and serves as a linkage between the extracellular matrix and 
cytoskeleton, playing a large roll in cell adhesion.163,164 The role of increased phosphorylation of 






Figure 4.2: Comparative analysis of the CDK5R1/p35 OE cardiac phospho-proteome  
A) Unsupervised hierarchical clustering of significantly phosphorylated proteins between 
CDK5R1/p35 OE and control littermate mice (CDK5R1/p35 OE  n = 6; control WT n = 5).  
B) Volcano plot representing proteins with significant differences in phosphorylated proteins 
when comparing CDK5R1/p35 OE cardiac tissue with control samples.  
*For each protein, significance is expressed as FDR adjusted p-value as a function of difference 
between samples (log2 fold change). FDR = 0.05, s0= 0.1. Significantly upregulated/downregulated 










-2.067 Asph aspartate beta-hydroxylase 2.02 
-1.951 Sorbs1 sorbin and SH3 domain containing 1 6.77 
-1.85 Htatsf1 HIV-1 Tat specific factor 1 2.63 
-1.808 Gja1 gap junction protein alpha 1 2.55 
-1.598 Palm paralemmin 3.78 
-1.501 Tbc1d4 TBC1 domain family member 4 2.9 
-1.454 Rap1gap2 RAP1 GTPase activating protein 2 3.92 
-1.452 Il10rb interleukin 10 receptor subunit beta 3.21 
-1.45 Plin1 perilipin 1 0.85 
-1.411 Leo1 




-1.41 Ythdc1 YTH domain containing 1 3 
-1.404 Cycs cytochrome c, somatic 5.41 
-1.341 Pi4k2a phosphatidylinositol 4-kinase type 2 alpha 5.91 
-1.314 Prkab1 protein kinase AMP-activated non-catalytic subunit beta 1 1.82 
-1.314 Ctnna3 catenin alpha 3 2.23 
-1.295 Cdk13 cyclin dependent kinase 13 3.92 
-1.287 Pspc1 paraspeckle component 1 1.33 
-1.273 Cdc42ep1 CDC42 effector protein 1 1.03 
-1.273 Tnni3k TNNI3 interacting kinase 1.68 
-1.272 Ttc7b tetratricopeptide repeat domain 7B 4.22 
-1.271 Acot7 acyl-CoA thioesterase 7 4.32 
-1.268 Frmd5 FERM domain containing 5 2.38 
-1.263 Tcea3 transcription elongation factor A3 2.78 
-1.263 Cic capicua transcriptional repressor 3.94 
-1.239 Fxr1 FMR1 autosomal homolog 1 3.08 
-1.236 Tcp11l2 t-complex 11 like 2 3.19 
-1.235 Gtf2f1 general transcription factor IIF subunit 1 2.27 
-1.234 Ank1 ankyrin 1 5.21 
-1.227 Ncl nucleolin 1.26 
-1.219 Tbc1d17 TBC1 domain family member 17 3.09 
5.611 Cap2 cyclase associated actin cytoskeleton regulatory protein 2 6.85 
5.022 Tln2 talin 2 7.49 
4.557 Cavin4 caveolae associated protein 4 5.89 
4.503 Usp10 ubiquitin specific peptidase 10 6.03 
4.32 Bcas3 BCAS3 microtubule associated cell migration factor 8.44 
4.31 Ephx2 epoxide hydrolase 2 7.65 
4.282 Ttn titin 5.1 
4.274 Plec plectin 6.64 
4.25 Ilrun 
inflammation and lipid regulator with UBA-like and 
NBR1-like domains 8.66 
4.178 Speg striated muscle enriched protein kinase 6.42 
4.152 Slc16a1 solute carrier family 16 member 1 7.43 
4.134 Dennd4c DENN domain containing 4C 7.39 
4.104 Tbc1d13 TBC1 domain family member 13 7.72 
4.088 Vps13c vacuolar protein sorting 13 homolog C 7.15 
3.958 Dtna dystrobrevin alpha 9.22 
3.92 Pex19 peroxisomal biogenesis factor 19 8.59 
3.873 Usp14 ubiquitin specific peptidase 14 7.8 
3.855 Tmem185a transmembrane protein 185A 6.76 
3.78 Ehd4 EH domain containing 4 7.34 
3.77 Ccdc93 coiled-coil domain containing 93 8.32 
3.685 Coro6 coronin 6 7.71 
3.677 Perm1 PPARGC1 and ESRR induced regulator, muscle 1 7.36 
3.67 Naca nascent polypeptide associated complex subunit alpha 6.07 
3.624 Ccdc8 coiled-coil domain containing 8 4.52 
3.589 Ociad1 OCIA domain containing 1 7.84 
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3.57 Flnc filamin C 4.69 
3.549 Sgpp1 sphingosine-1-phosphate phosphatase 1 6.26 
3.517 Synpo synaptopodin 5.93 
3.491 Dmac1 distal membrane arm assembly complex 1 6.7 
3.486 Dact3 dishevelled binding antagonist of beta catenin 3 6.91 
 
Table 4.2: Graph and corresponding list of the top 30 proteins with a decrease/increase in 
phosphorylation based on fold change (log2 ratio) in CDK5R1/p35 OE mouse cardiac tissue 
 
Proteins with a significant decrease in phosphorylation in the Cdk5 deficient cohort, and 
opposing increase in phosphorylation in the CDK5R1/p35 OE cohort were considered potential 
candidates for cardiac-related Cdk5 substrates. For further narrowing of substrate candidates,  
specific phospho-sites of proteins with significant phosphorylation changes that were decreased 
in Cdk5 deficient mice and subsequently increased in CDK5R1/p35 OE mice were analyzed. A 
total of 18 common proteins with an overall opposing changes in phosphorylation (decreased 
phosphorylation in Cdk5 deficient mice and increased phosphorylation in CDK5R1/p35 OE 
mice) were identified. The list of identified substrate candidates can be found in Figure 4.3. One 
of the identified substrates was CaV1.2—the Cdk5 substrate candidate that our lab had identified 






Figure 4.3: |Potential Cdk5 substrates  
A) List of proteins with a significant decrease in phosphorylation in Cdk5 deficient mice, and 
subsequent increase in phosphorylation in CDK5R1/p35 OE mice.  





Pathway analysis of the potential substrate list of Cdk5 as outlined in Figure 4.3 revealed 
hits associated with microtubule dynamics, transport of molecules, muscle contraction/function 
and cardiac contractility (Table 4.3). These proteins play an essential role in cell-to-cell adhesion, 
which is also a major function of Cdk5 in the brain. Cdk5 is known to phosphorylate cytoskeletal 
proteins, signaling molecules, ion channels and regulatory proteins involved in microtubule and 
actin dynamics, cell-cell/cell-ECM adhesion and cytoskeletal regulation. 114-117 
 
Pathway Hits Potential Cdk5 substrates 
Microtubule Dynamics Atp2b1, Gab1, Palld, Pde4dip, Prune2, Slc9a1, Tacc2 
Transport of Molecules Atp1a1, Atp2b1, Cav1.2, Gab1, Ppp1r3a, Slc9a1 
Muscle Contraction Atp1a1, Atp2b1, Cav1.2, Sgca 
Function of Muscle Atp1a1, C10orf71, Gab1, Sgca 
Cardiac Contractility Atpa1, Gab1, Slc9a1 
Table 4.3: |IPA pathway analysis of 18 identified potential phospho-targets of Cdk5.  
 
Lastly, potential phospho-sites in proteins of interest were further narrowed down 
dependent on whether they followed the known Cdk5 consensus motif “(S/T)PX(K/H/R).” The 
two proteins/phospho-sites that met these criteria were (1) Txlnb on Serine 78 and (2) density 
regulated re-initiation and release protein on Serine 73 (Denr). As previously mentioned, Txlnb is 
a cardiac- and skeletal-muscle enriched protein with high cell-type expression in cardiomyocytes 
(Fig 4.4) Currently, little is known about Txlnb’s physiological function. One group published an 
abstract hypothesizing a role for Txlnb in cardiac protein proteostasis via regulation of protein 
synthesis, autophagy, proteosome degradation and ubiquitination. Txlnb knockout mice display 
increased protein ubiquitination and decreased proteasome activity—an increase in protein 
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ubiquitination has also been associated with the pathophysiology of DCM.143,165 Another group 
recently published a paper identifying TXLNB in humans as a novel DCM-associated gene.144 
Lastly, in a mouse model of myotonic dystrophy, Txlnb expression was found to be significantly 
downregulated.166 Myotonic dystrophy is an autosomal dominant disorder of the skeletal and 
smooth muscle caused by an expansion of “CUG” repeats.167 Individuals with myotonic dystrophy 
experience progressive muscle wasting and weakness, along with prolonged muscle contractions. 
Myotonic dystrophy also has cardiac-manifestations that include conduction disturbances, 
arrhythmias and cardiomyopathies.168  
 
 
Figure 4.4: Cardiomyocytes exhibit highest cell type expression of TXLNB |RNA single cell 
type specificity demonstrates highest cell-type specific expression of TXLNB in cardiomyocytes. 
(Figure taken from proteinatlas.org)  
 
The second potential substrate identified based on proteomic data is Denr. DENR is an 
mRNA translation factor whose expression has been postulated to be regulated by direct cell to 
cell contact.169 There is very little known about the physiological and functional roles DENR aside 
from its expression in various tissue types. While DENR is found to be expressed in cardiac tissue 





Figure 4.5: Tissue-specific expression of DENR |RNA tissue-specific expression of DENR. 
Medium expression is found in heart muscle. (Figure taken from proteinatlas.org)  
 
 To further explore Txlnb and Denr as potential Cdk5 substrates, a proximity ligation assay 
(PLA) was performed. In situ proximity ligation assay’s combine oligo-labeled antibodies with 
ligation and PCR amplification to allow for detection of protein-protein interactions. Such 
detection can be used for epitope-epitope interaction on one protein, or protein-protein interaction 
between two co-localized proteins. In summary, two primary antibodies (from different species 
origins) are each bound by a positive or negative PLA probe—PLA probes are secondary 
antibodies covalently bound to a short oligonucleotide. Upon addition of ligase (and if 
epitopes/proteins are within a <40 nm proximity), the positive and negative PLA probes can 
hybridize and form a rolling circle DNA template for amplification with the addition of DNA 
polymerase. Lastly, fluorescent probes are added to the amplified DNA, allowing for detection 




Figure 4.6: Proximity ligation assay schematic  
 In situ PLA was used to determine co-localization between Cdk5-Txlnb and Cdk5-Denr. 
Whole heart ventricular tissue sections from WT mice and Cdk5 deficient mice were 
deparaffinized and a proximity ligation assay was performed using the Duolink in Situ Proximity 
Ligation Assay Fluorescence kit for mouse/rabbit antibodies. Cdk5 deficient mouse ventricle 
embedded tissue sections were used as a negative control. Results from the PLA of Cdk5-Txlnb 
revealed co-localization of the two proteins in WT mice (Fig 4.7), while Cdk5-Denr did not give 
a detectible signal (image not included). While it is possible that Denr may not be a potential 
cardiac-specific Cdk5 substrate, technical issues could explain why the PLA did not give a result 
with Cdk5-Denr. If there was a lack of antibody-epitope compatibility for the Denr protein, one 
would not get a detectible fluorescent signal. It is also possible that the Cdk5-Denr complex is 
masked by other molecules in the cardiac tissue sample, or the epitope used for antibody 




Figure 4.7: Protein-protein interaction between Cdk5 & Txlnb |Representative confocal 
fluorescent and bright field images of control (example from female WT) and Cdk5 deficient 
(example from female Cdk5fl/lf) mouse used with proximity ligation assay (PLA, SIGMAR1-hERG 
red) and DAPI (blue) staining; scale bar, 10 µm. White triangles indicate location of co-localization 















 Protein phosphorylation is the most common post-translational modification necessary for 
the regulation of protein function, cell signaling and biological pathways.170 The goal of this 
chapter is to identify potential novel cardiac-specific substrates of Cdk5. Cdk5 is a proline directed 
serine/threonine kinase that phosphorylates its substrate targets by adding a phosphate group from 
ATP to a targeted amino acid residue. The role of Cdk5 has been extensively studied in the brain, 
and as a result, 19 different neuronal-specific substrates have been identified.21,29  Prior findings 
from the Yazawa lab as well as findings reported in this thesis have demonstrated a critical role 
for Cdk5 in cardiac function and cardiac disease pathophysiology. Exactly how Cdk5 modulates 
cardiac function and impacts cardiac pathophysiological conditions remains to be understood. By 
identifying cardiac-specific Cdk5 substrates, we may be able to uncover novel mechanisms 
underlying cardiac function and cardiovascular disease states.  
 To identify phospho-substrate targets, phosphoproteomic LC-MS/MS was performed on 
both Cdk5 deficient and CDK5R1/p35 OE mouse cardiac tissue. Differential expression analysis 
of the Cdk5 deficient and CDK5R1/p35 OE phospho-proteome revealed significant 
phosphorylation changes in proteins associated with cell-cell adhesion and cardiac contractility. 
Phosphoproteomic analysis confirmed a lack in difference between the Cdk5fl/+ and Cdk5fl/fl 
cohorts, once again, consistent with what was observed in echo and histological results.  
 Interestingly, while CDK5R1/p35 OE hearts did not have any significant global proteome 
changes (FDR = 0.05, S0=0.1), there were significant changes observed in the phospho-proteome, 
with over 3,000 significantly differentially phosphorylated proteins/protein isoforms identified. 
By activating Cdk5, it seems a downstream phosphorylation cascade may have been activated. 
When certain kinases are continuously activated, it can subsequently activate downstream 
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signaling molecules, in turn, causing this phosphorylation cascade. To confirm the top two 
candidate Cdk5 substrates, a PLA was performed to look for co-localization of Cdk5 and 
Txlnb/Denr. Co-localization was observed between Cdk5 and Txlnb only in WT mouse cardiac 
tissue. This co-localization was no longer evident in Cdk5 deficient mouse cardiac tissue. The 
investigation of protein phosphorylation in vivo is limited, with analysis beyond phospho-
proteomics reduced to in vitro biochemical assays; kinases removed from their physiological 
environment don’t always behave the same way in vitro. Limitations associated with such analysis 
include experiment-specific reagents/conditions that alter availability of phospho-substrates and 
the phosphorylation state of the substrate in the cell potentially preventing it being utilized as a 
substrate in non-physiological assay.171 It is also possible that the site can only be phosphorylated 
when in a given complex. The next step in adequate confirmation of the identified phospho-site on 
Txlnb (Serine 78) and Denr (Serine 73) involves phosphoantibody production. While this is a 
technically challenging and time-consuming endeavor, our lab has prior expertise in antibody 












Phospho-Proteomics by Mass Spectroscopy for Cdk5 Deficient Cohort  
 For phospho-proteome analysis, 11 desalted fractions were enriched for phosphopeptides 
using a mixture of MagReSyn Ti-IMAC and Zr-IMAC resins according Resyn Bioscience 
instructions. In briefly, 200 µg of labeled peptide were dissolved in 0.2 ml of binding buffer (80% 
Acetonitrile, 1M glycolic acid and 5% TFA) and incubated with equilibrated (10 µl of each Ti-
IMAC and Zr-IMAC) resins at room temperature for 30 min, and the resin was washed 3 three 
times to remove the unbound, non-phosphorylated peptides. Phospho-peptides were eluted using 
1% ammonium hydroxide. The enriched phospho-peptides were further de-salted with SDB-SCX 
stageTip and each fraction dried down in a speed-vac. Dried phospho-peptides were in dissolved 
in 10 µl of (3% acetonitrile/ 0.1% formic acid) injected using MSA-SPS-MS3 and NL-SPS-MS3 
methods (ref. M2). The UltiMate 3000 UHPLC system and EASY-Spray PepMap RSLC C18 50 
cm x 75 μm ID column coupled with Orbitrap Fusion were used to separate fractioned peptides 
with a 5-30% acetonitrile gradient in 0.1% formic acid over 45 min at a flow rate of 250 nL/min. 
After each gradient, the column was washed with 90% buffer B for 10 min and re-equilibrated 
with 98% buffer A (0.1% formic acid, 100% HPLC-grade water) for 40 min. Phosphopeptide 
analysis, two methods were used for each fraction. For both methods, the full MS spectra were 
acquired in the Orbitrap at a resolution of 120,000. The 10 most intense MS1 ions were selected 
for MS2 analysis. Following the acquisition of each MS2 spectrum, a synchronous-precursor-
selection (SPS)-MS3 scan was collected on the Top 10 most intense ions in the MS2 spectrum. 
The isolation width was set at 0.7 Da, and isolated precursors were fragmented using two methods. 
In the first method, we used collision-induced dissociation (CID) at normalized collision energy 
(NCE) of 35% with MultiStage Activation (MSA), and in the second method with NL-triggered 
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MS3 using higher energy collision-induced dissociation (HCD) at normalized collision energy 
(NCE) of 35%. SPS-MS3 precursors were fragmented by higher energy collision-induced 
dissociation (HCD) at  NCE of 65% and analyzed using the Orbitrap. 
Raw mass spectrometric data were analyzed using Proteome Discoverer 2.4 to perform 
database search and TMT reporter ions quantification. TMT tags on lysine residues and peptide N 
termini (+229.163 Da) and the carbamidomethylation of cysteine residues (+57.021 Da) was set 
as static modifications, while the oxidation of methionine residues (+15.995 Da), deamidation 
(+0.984) on asparagine and glutamine and phosphorylation (+79.966) on serine, threonine, and 
tyrosine were set as a variable modification. Data were searched against a UniProt Mouse with 
peptide-spectrum match (PSMs) and protein-level FDR at 1% FDR. The signal-to-noise (S/N) 
measurements of each protein will be normalized so that the sum of the signal for all proteins in 
each channel was equivalent to account for equal protein loading.   
 
Phospho-Proteomics by Mass Spectroscopy for CDK5R1/p35 OE Cohort  
For phospho-proteome analysis, ~3mg bulk mixed TMT-labeled samples were dried and 
desalted using a 200 mg Sep-Pak solid-phase extraction column. Desalted peptides were enriched 
for phospho-peptides using a mixture of MagReSyn Ti-IMAC and Zr-IMAC resins according 
Resyn Bioscience instructions. In briefly, 3 mg of labeled peptide were dissolved in 1 ml of binding 
buffer (80% Acetonitrile, 1M glycolic acid and 5% TFA) and incubated with equilibrated 300 µl 
(150 µl of each Ti-IMAC and Zr-IMAC) resins at room temperature for 30 min, and the resin was 
washed 3 three times to remove the unbound, non-phosphorylated peptides. Phospho-peptides 
were eluted using 1% ammonium hydroxide. The enriched phospho-peptides were further 
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fractionated in eight fractions using the High pH Reversed-Phase Peptide Fractionation Kit 
(ThermoFisher Scientific; catalog #: 84868) and each fraction dried down in a speed-vac.  
Dried phospho-peptides were in dissolved in 10 µl of (3% acetonitrile/ 0.1% formic acid) 
injected using MSA-SPS-MS3 and NL-SPS-MS3 methods.172 The UltiMate 3000 UHPLC system 
and EASY-Spray PepMap RSLC C18 50 cm x 75 μm ID column coupled with Orbitrap Fusion 
were used to separate fractioned peptides with a 5-30% acetonitrile gradient in 0.1% formic acid 
over 45 min at a flow rate of 250 nL/min. After each gradient, the column was washed with 90% 
buffer B for 10 min and re-equilibrated with 98% buffer A (0.1% formic acid, 100% HPLC-grade 
water) for 40min. Phospho-peptide analysis, two methods were used for each fraction. For both 
methods, the full MS spectra were acquired in the Orbitrap at a resolution of 120,000. The 10 most 
intense MS1 ions were selected for MS2 analysis.  
Following the acquisition of each MS2 spectrum, a synchronous-precursor-selection 
(SPS)-MS3 scan was collected on the Top 10 most intense ions in the MS2 spectrum. The isolation 
width was set at 0.7 Da, and isolated precursors were fragmented using two methods. In the first 
method, we used collision-induced dissociation CID at normalized collision energy (NCE) of 35% 
with MSA, and in the second method with NL-triggered MS3 using higher energy collision-
induced dissociation HCD at NCE of 35%. SPS-MS3 precursors were fragmented by HCD at NCE 
of 65% and analyzed using the Orbitrap. 
 
Analysis of Raw Phosphoproteomic Mass Spectrometric Data for both Cdk5 deficient and 
CDK5R1/p35 OE Cohorts 
Raw phospho-proteome mass spectrometric data were analyzed using Proteome 
Discoverer 2.2 to perform database search and TMT reporter ions quantification. TMT tags on 
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lysine residues and peptide N termini (+229.163 Da) and the carbamidomethylation of cysteine 
residues (+57.021 Da) was set as static modifications, while the oxidation of methionine residues 
(+15.995 Da), deamidation (+0.984) on asparagine and glutamine and phosphorylation (+79.966) 
on serine, threonine, and tyrosine were set as a variable modification. Data were searched against 
a UniProt Mouse with peptide-spectrum match (PSMs) and protein-level FDR at 1% FDR. The 
signal-to-noise (S/N) measurements of each protein will be normalized so that the sum of the signal 
for all proteins in each channel was equivalent to account for equal protein loading.   
 
Analysis of Phosphoproteomic Results for both Cdk5 deficient and CDK5R1/p35 OE Cohorts  
Phospho-peptide identification and quantification were imported into Perseus MaxQuant 
for statistical analysis (FDR<0.05) to identify proteins demonstrating statistically significant 
changes in abundance.125 The workflow used for phosphoproteomic comparison is comparable to 
the workflow previously outlined in Sections 2.4/3.4, respectfully.   
 
Identifying Cardiac-Specific Cdk5 Substrates  
To narrow down potential phosphorylation targets of Cdk5, the list of all significantly 
phosphorylated proteins (FDR<0.05) from the Cdk5 deficient phosphoproteomic dataset and 
CDK5R1/p35 OE dataset were pasted into an excel sheet. Next, a “=VLOOKUP” function was 
utilized to identify the associated phospho-log ratio from each of the two cohorts. Significantly 
changed proteins that did not appear in both cohorts were filtered out of the merged dataset. Then, 
leveraging excels “IF” function to create a “0” or “1” dummy variable that indicates an inverse 
relationship (“0” being no inverse relationship observed and “1” being the presence of an inverse 
relationship), the dataset was filtered to include proteins that had an increase in phosphorylation 
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in the CDK5R1/p35 OE cohort and corresponding decrease in phosphorylation in the Cdk5 
deficient cohort. The final list consisted of 23 proteins.  
As the significant changes in protein phosphorylation were cumulatively derived and not 
based on specific phospho-site (limitations of mass-spec output format and subsequent analysis), 
significantly changed phosphorylation sites were manually compared between the Cdk5 deficient 
and CDK5R1/p35 OE cohorts. Sites that were overlapping between both proteins and that followed 
the known CDK5 consensus sequence were utilized for further analysis.   
 
Proximity Ligation Assay   
A proximity ligation assay was performed using the Duolink in Situ Proximity Ligation 
Assay Fluorescence kit for mouse/rabbit antibodies (Sigma-Aldrich, catalog #: DUO92101). 
Standard PLA for tissue in situ were adhered to.173,174 In summary, 5µM-thick sections of paraffin 
embedded whole heart ventricular tissue (see protocol in “Mouse Cardiac Tissue Sampling” 
method section) were deparaffinized and rehydrated by immersing in xylene, ethanol and distilled 
water. Using a hydrophobic barrier pen, a circle was draw on the slide surrounding each tissue 
section. Slides were washed three times with PBS, permeabilized for 30 minutes at room 
temperature with 0.2% Triton X-100 in PBS and then washed another three times with PBS. 
Permeabilized samples were blocked with blocking solution from the Duolink kit for 1 hour at 
37C in a humidity chamber followed by three more washes with PBS.  
Next, sections on slides were co-incubated with a 1:500 dilution of mouse anti-CDK5 
antibody (Santa Cruz Technology; catalog #: sc-6247) and either: (1) IHC-plus Polyclonal Rabbit 
anti-human TXLNB Antibody (LSBio; catalog #: LS-A8163) at 1:1000 dilution or (2) Rabbit anti-
human Polyclonal DENR Antibody (Novus Biological; catalog #: NBP2-13913) at a 1:1000 
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dilution with Duolink Antibody Diluent for 24 hours. After incubation, slides were washed and 
subsequently incubated with the PLUS and MINUS probes in a 1:5 dilution with Duolink Antibody 
Diluent for 1 hour at 37 C in a preheated humidity chamber. After washing, Ligase from the kit 
was added to the slides in a 1:5 dilution with Ligation Buffer and Ultrapure water. The slides were 
incubated for 30 minutes in a pre-heated humidity chamber at 37 C.  
 
Imaging of PLA Fluorescence Signals  
The PLA fluorescence signals were imaged using an inverted Nikon Eclipse Ti-U Inverted 
Fluorescence microscope with a Nikon 40x objective lens (CFI S Flour, Bright Field; NA, 0.90; 
W.D. 0.30mm; cover glass thickness, 0.17), standard DAPI and RFP filter sets (Chroma), Lambda 














5.1 Translational Relevance of CDK5  
One of the hallmark indicators of cardiac dysfunction is an alteration in cardiac protein 
phosphorylation. Protein phosphorylation is a key regulator of cardiac contractility, structural 
integrity and metabolism.139,171,175 Protein phosphorylation by a number of kinases including Ca2+-
calmodulin protein kinase (CAM-PK), protein kinase C (PKC), ERK’s and mitogen-activated 
protein kinases (MAPK’s) has been studied in a number of cardiac pathophysiological 
conditions.171 What remains to be elucidated, however, is how phosphorylation triggers 
modulation in protein activity and subsequent downstream pathophysiological effects.  
One such cardiovascular disease state in which a dysregulation of phosphorylation has been 
implicated is heart failure. Heart failure is a life-threatening condition in which the heart’s ability 
to fill up with or to eject blood is impaired. This insufficient cardiac output prohibits a sufficient 
amount of blood from being delivered to tissue throughout the body.176 Disturbance in cardiac 
protein phosphorylation is associated with mechanisms involved in cardiac dysfunction and 
subsequent heart failure.172 For example, altered Ca2+ handling and impaired myofilament 
contraction have been linked to defects in phosphorylation of cardiac troponin I via PKA. Altered 
phosphorylation of such contractile proteins are associated with end stage heart failure.177  
In collaboration with the Junco Warren lab and Dr. Stavros Drakos at the University of 
Utah, our lab obtained myocardial tissue from human donors who passed away due to either heart 
failure or non-cardiac related causes. A total of 4 control tissue samples and 5 heart failure samples 
were obtained (Table 5.1). I decided to look at protein expression levels of CDK5 and p35 in each 
cardiac tissue sample in order to: (1) detect expression of CDK5 in human cardiac tissue, (2) 
91 
 
determine whether there is a correlation between heart failure and CDK5/p35 expression and (3) 




Table 5.1: Information on human heart donors| Information concerning heart donors’ gender, 
age, race, body weight, height, cause of death, cardiac/respiratory arrest status, 
ischemia/coronary artery disease status, ejection fraction, and heart failure etiology are listed 
above. Samples and corresponding information was obtained from collaborators in the Junco 
Warren lab at the University of Utah.  
 
  
Analysis of CDK5 and p35 expression via western blot assay revealed a significant 
correlation between heart failure status and an increase in CDK5 and p35 expression, with both 
CDK5 and p35 being significantly higher in heart failure samples (Fig. 2—A,B). This data was 
really interesting, as we had initially hypothesized that there would be a decrease in CDK5 
expression associated with heart failure. During heart failure, the goal of the myocardium is to 
compensate for cardiac output. One potential explanation for this observed increase in CDK5/p35 
expression pattern could be a result of a compensatory mechanism (i.e. cardiac remodeling, 
increased heart rate) associated with heart failure and overall cardiac dysfunction.178 As part of 






Figure 5.1: Expression of CDK5 and p35 in human heart failure and control samples |  
A,B) Western blot analysis of CDK5 and p35 from human myocardial tissue collected from the 
left ventricle apex of individuals who passed away due to heart failure or non-cardiac related 
causes. A total of 4 control tissue samples and 5 heart failure samples were used. Band intensities 




5.2 Final Thoughts & Future Directions 
 Previously, a role for CDK5 in cardiac function and cardiovascular disease states had not 
been explored. CDK5 has been established in the literature as a unique CDK, having cell-cycle 
independent functions in a number of biological systems/processes including insulin secretion, 
metabolism, myogenesis, the immune system, the lymphatic system, cell motility and cell 
migration. 26  Furthermore, the majority of CDK5’s well-known functions have been in the brain. 
As a result of such neuro-focused studies, the majority of elucidated human CDK5 substrates are 
neuronal-tissue specific.  
In this study, two novel mouse models were established in order to determine Cdk5’s 
impact on cardiac function: (1) an inducible Cdk5 deficient mouse model and (2) an inducible 
Cdk5 activation mouse model. Tam inducible cardiac-specific Cdk5 deficiency in adult mice 
resulted in severe systolic dysfunction, with significant decreases in FS, EF, LVEDD and LVEDF. 
Histological analysis showing significant enlargement of the LV along with LV wall thinning. 
Additionally, mononuclear cell infiltrate and modest evidence of collagen deposition were 
observed based on H&E and MT stains of paraffin embedded cardiac tissue sections. Lastly, global 
proteomic LC-MS/MS studies revealed changes in protein abundance indicative of a cardiac 
enlargement/DCM-like phenotype. Analysis of biological and functional pathways associated with 
proteome changes revealed a majority of differentially expressed proteins implicated in cell-
adhesion. In the heart, the contractile ability of the cardiac muscle is maintained by integrity and 
synchronicity of the cell-to-cell junctions.119 In heart failure as well as cardiomyopathies, 
significant alterations in cell-to-cell junctions are observed. 120,121 It is therefore plausible that 
CDK5 plays a significant role in the regulation of cell-to-cell adhesion in cardiac tissue.   
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 Interestingly, when analyzing a model of Cdk5 activation (via OE of its activator p35), a 
striking cardiac phenotype was not observed. Echo recordings revealed a moderate reduction in 
systolic function as defined by reduced LVEF and LVFS. Again, such reductions were not nearly 
as significant/severe in comparison with the Cdk5 deficient mouse model. Furthermore, a lack of 
significant morphological and histological changes were noted along with a lack of changes to the 
global proteome. The only significant protein change detected by global proteomic analysis was a 
~1.5 fold increase in Cdk5’s activator, p35, which we exogenously overexpressed to establish the 
Cdk5 activation model. It is evident that alterations in baseline/homeostatic levels of Cdk5 results 
in cardiac impairment.  
 In addition to differences in control vs Cdk5 deficient/Cdk5 activation phenotypes, further 
phenotypical differences were observed based on gender of mice. Male mice experienced more 
severe systolic effects from Cdk5 deficiency than did female mice. Furthermore, the global 
proteome changes in Cdk5 deficient male mice were more significant than were female mice. 
While a minimal number of gender-specific differences were noted in the global proteome of 
control mice, a significant number of gender-related changes in the phospho-proteome were 
observed (Fig. 5.2). Phospho-proteome differences could be a potential explanation for gender 
bias towards males in predisposition as well as manifestation of cardiovascular disease. Notedly, 
DCM along with heart failure and a number of additional cardiac disease states have an increased 
incidence rate in men vs women.179 Gender difference studies are currently being pursued as part 
of future directions for this project. A deeper understanding of molecular mechanisms underlying 
gender difference and response to cardiovascular disease states will be useful for precision 




Figure 5.2: Differences in the global vs phospho-proteome of control mice  
 
Limitations of spatiotemporal Cre-recombinase mediated mouse models targeted to cardiac 
tissue are present. Both Tam as well as Cre-recombination are known to have baseline levels of 
transient cardiotoxic effects. These effects can be minimized and accounted for with adequate Tam 
dosing optimization as well as utilization of appropriate experimental controls. In this study, we 
demonstrate minimal observed toxicity with optimized Tam dosing in both WT and WTMCM 
cohorts.  
A comparison of the phospho-proteome of Cdk5 deficient and Cdk5 activation mice 
allowed for identification of potential phospho-substrates in the heart. Phosphoproteomic and PLA 
studies revealed Txlnb, an understudied but highly expressed cardiac protein recently implicated 
in DCM, as a potential cardiac-specific substrate. As part of future directions, a phosphoprotein 
antibody for Txlnb—Serine78 is being produced. Furthermore, we plan to conduct knock-in 
experiments utilizing CRSIPR/Cas9 to generate mutant mice with an Ala-substitution on Txlnb-
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Serine78. Validation of Cdk5 phosphorylation of Txlnb on the suspected phospho-site will provide 
further validation of the accuracy of our findings. Identification of Cdk5-cardiac specific phospho-
targets may help us elucidate a mechanism by which Cdk5 regulates cardiac pathophysiological 
function.   
 Notedly, a role for Cdk5 in cardiac development was not discussed in this thesis. 
Preliminary findings from our lab have suggested that cardiac-specific depletion of Cdk5 caused 
embryonic lethality (~E14.5) due to cardiac dysfunction in the mouse (not shown). As part of 
future efforts by the lab, analysis of embryonic heart phenotypes in Cdk5 cardiac conditional 
knockout mice are currently being analyzed—this includes heart contraction assays, cardiac Ca2+ 
imaging, gene expression profiling and histology. Preliminary results using Cdk5 conditional 
knockout embryos indicate that Cdk5 is essential for heart development.  
 Lastly, as part of a follow-up to this project, potential therapeutic applications of p35 OE 
for cardiomyopathies are being explored. An adeno-associated virus (AAV) vector system has 
already been constructed to overexpress CDK5R1/p35. The AAV was constructed using a pAAV9 
backbone, driven by the cardiomyocyte specific gene expression promoter, cardiac troponin T 
(cTNT) (Fig 5.3). Additionally, this construct will allow for YFP fluorescent intensity readout as 
it is correlated to p35 expression due to the self-cleaving peptide P2A system used in the construct. 
Successful infection using the aforementioned construct has already been confirmed using iPSC-
CM’s in the lab. The established AAV is also appropriate for use in in vivo mouse models, while 
multiplicity of infection has yet to be validated. We are also establishing both a CDK5 and p35 
shRNA for translational application in heart failure models. Additionally, the effects of p35 OE in 
doxorubicin-induced DCM as well as Duchenne Muscular Dystrophy related DCM are being 
explored by our lab. Outcomes of this study as well as future directions provide new insight into 
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cardiac function, novel players in cardiovascular disease states, as well as the potential to be 
translational for development of new therapeutic targets for heart disease.  
 
 
Figure 5.3: pAAV9-cTNT::hCDK5R1/p35 construct map | pAAV-YFP-2A-p35 viral construct. 
p35/YFP expression is driven by the cTnT promoter. Addgene #69915 vector is used as the 




















Human Heart Myocardial Samples  
Flash frozen samples of human myocardial tissue were received from the Junco Warren 
lab at the University of Utah. Myocardial tissue was collected from the left ventricle apex of donor 
hearts that did not meet transplant requirements for non-cardiac related reasons (control samples). 
Left ventricular apex myocardial tissue was also collected from individuals who had passed away 
due heart failure (heart failure samples). A total of 4 control tissue samples and 5 heart failure 
samples were used for western blot analysis. The samples used for this study had been used for 
published studies from the Junco Warren lab.180  
 
Western Blot of Human Myocardial Samples 
Each human myocardial tissue sample was homogenized and subsequently lysed using 
lysis buffer containing 1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl (pH 7.4) and 1x protease 
inhibitor cocktail (Sigma-Aldrich; catalog #: P8340). Following lysis, protein concentrations were 
measured for each sample using a Pierce Bicinchoninic Acid assay kit (ThermoFisher Scientific; 
catalog #: 23225). Samples were prepared to a final amount of 20 μg of protein per well from each 
of the nine samples. Samples were denatured in 2× sodium dodecyl sulfate (SDS) sample 
buffer containing 8M Urea, 40 mM Tris-HCl, 2% (SDS), 10% beta-mercaptoethanol and 0.01% 
bromophenol blue. Each sample was then boiled on a heat block at 95 C for 5 minutes. SDS-
polyacrylamide gel electrophoresis was run by loading samples onto a Tris-HCl SDS page gel 
(containing 10% Acrylamide-Bis) with a 5% stacking gel and 10% separation gel along with the 
ladder. All samples were subsequently to electro-transferred to Polyvinylidene difluoride (PVDF) 
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membranes using XCell SureLock Mini-Cell and XCell Blot Module system (Life Technologies; 
catalog #: EI0002) for approximately 14 hours/overnight. 
The second/following day, membranes were blocked using 5% non-fat dry milk in Tris-
based saline solution with Tween, 50 mM Tris-HCl, 150 mM NaCl, and 0.1% Tween (TBS-T) for 
90 minutes at room temperature and subsequently stained with primary antibody diluted in 
blocking buffer overnight. The following two antibodies were used for Western blot: (1) anti-Cdk5 
rabbit monoclonal Ab, (abcam; catalog #: ab40773) at a dilution of 1:1000 (2) anti-p35/p25 rabbit 
monoclonal antibody (Cell Signaling; catalog #:C64B10) at a dilution of 1:1000.   
On the third/last day, PVDF membranes were incubated with a secondary goat anti-rabbit 
antibody (ThermoFisher Scientific; catalog #: 31460) at a 1:10,000 dilution in 5% nonfat dry milk 
+ TBS-T blocking solution for one hour at room temperature. After secondary antibody stain, 
membranes were incubated with the Pierce ECL Western blotting substrate (ThermoFisher 
Scientific; catalog #: 32209) for chemiluminescence followed by exposure to X-ray films in a dark 
room. Following CDK5/p35 staining, membranes were stripped with buffer containing 62.5mM 
Tris-HCl, 2% SDS, 114mM beta-mercaptoethanol at 42oC for 15-20 minutes, followed by 
washing six times with PBS. A second round of immunoblotting was done for GAPDH in order 
to normalize band intensities. Band intensities for CDK5 & p35 antibodies were optimal at 1 hour 
exposure, and GAPDH was optimal after touch exposure. Protein band intensities of CDK5/p35 
were quantified using ImageJ and were normalized to their corresponding GAPDH values. Statical 
significance was conducted in GraphPad Prism using an unpaired two-tailed t-test, with 7 degrees 





For western blot protein expression quantification, protein band intensities of CDK5 and 
p35 were quantified using ImageJ and were normalized to their corresponding GAPDH values. 
Statical significance was conducted in GraphPad Prism using an unpaired two-tailed t-test, with 7 
degrees of freedom. For analysis of the correlation between EF and CDK5/p35 protein expression, 
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